

POSTER PRESENTATIONS

All Scientific Posters have been arranged into the following categories and numbers:

Category	Poster Number
ARV-based Prevention	
Mother-to-child Transmission	P001–P009
Pep/PrEP	P010–P017
Treatment as Prevention (TasP)	P018–P020
Treatment Strategies	
New Treatments and Targets	P021–P029
Target Populations	
Adolescents and Children	P031–P034
Women	P035–P039
Late Presenters	P040–P042
Naïve Patients	P043–P049
Primary Infection	P050–P053
Experienced Patients	P054–P060
IDUs	P061–P065
Strategies	
Adherence	P066–P076
Cure	P077–P079
Simplification	P080–P092
Switch Studies	P093–P113
Other	P114–P141
Opportunistic Infections	
Tuberculosis	P142–P149
Others	P150–P152
Co-morbidities and Complications of Disease and/or Treatment	
Ageing	P153–P168
Bone	P169–P173
Cardiovascular	P174–P188
Malignancies	
AIDS-defining	P189–P191
Non-AIDS-defining	P192–P199
Metabolic	P200–P207
Neurological	P208–P217
Renal	P218–P227
Other	P228–P247

POSTER PRESENTATIONS (continued)

Viral Hepatitis	P248–P300
Clinical Pharmacology	P301–P319
Community Initiatives	P320–P324
Models of Care	
Cost-effectiveness	P327–P331
Evaluation of ARV Delivery and Coverage	P332–P339
Late Presenters	P340–P344
Virology and Immunology	
Biomarkers/Tropism	P345–P351
Resistance	P352–P370
Other	P371–P374

POSTER PRESENTATIONS (continued)

ARV-based Prevention

- P001 High prevalence of hepatitis C co-infection and adverse pregnancy outcomes among HIV-infected pregnant women in Switzerland**
Aebi-Popp, K; Glass, T; Rudin, C; Martinez de Tejada, B; Hoesli, I; Grawe, C; Fischer, T; Duppenhaler, A; Rauch, A; Kahlert, C (Bern, Switzerland)*
- P002 A mother-to-child HIV-1 transmission bottleneck? A new understanding of the selection biases underlying successful perinatal infection**
Noble, C; Adland, E; Naidoo, V; Ndung'u, T; Goulder, P (Oxford, UK)*
- P003 Raltegravir in HIV-1-infected pregnant women: mother-to-child transmission (MTCT) prophylaxis and children safety case series**
Soares Medeiros, M; Pires Moreira, H; Antonio Gomes Arruda, E; Austregesilo Correa, E; Camelo de Sales, Y; Facanha Diogenes Teixeira, G; Aragao Ribeiro, E; Silveira Dantas, R (Fortaleza, Brazil)*
- P004 Prophylactic antiretroviral treatment in new-born infants from HIV-positive mothers in 2012–2015, for the North-Eastern part of Romania**
Manciuc, C; Vata, A; Nicolau, C; LARGU, A (Iasi, Romania)*
- P005 Determinants and risk of HIV infection among HIV-exposed infants in Western Ethiopia**
Duken, E; Regea, D; Siyum, O (Jimma, Ethiopia)*
- P006 Preventing mother-to-child transmission of HIV in a general hospital: are we following the guidelines?**
Awosusi, F; Al-Harbi, M (London, UK)*
- P007 Influence of HIV infection in choosing to terminate pregnancy**
Campoia, E; Pedro, L; Azevedo, F; Pinho, R; Simão, M; Santos, C; Faria, D; Santos, C; Arez, L (Portimão, Portugal)*
- P008 The association between preterm delivery and the risk of mother-to-child transmission of HIV**
Posokhova, S; Petrovych, S; Shevchenko, S (Odessa, Ukraine)*
- P009 Efficacy of prophylactic antiretroviral treatment in new-born infants from HIV-positive mothers in 2012–2014, for the North-Eastern part of Romania**
Manciuc, C; Prisacariu, L; Nicolau, C; LARGU, A (Iasi, Romania)*
- P010 Compliance of fixed-dose single tablet EVG/COBI/FTC/TDF (Stribild) regimen versus LPV/r/d4T/3TC for PEP in sexual assault victims: a retrospective sequential period study**
De Wit, S; Libois, A; Mols, P; Malinverni, S (Brussels, Belgium)*
- P011 Increased rate of Chlamydia trachomatis infection after being prescribed PrEP**
Nguyen, V; Trottier, H; Gbego Tossa, H; Charest, L; Longpré, D; Lavoie, S; Cadieux, M; Thomas, R (Montréal, Canada)*
- P012 Risk perception in MSM taking PrEP**
Boccino, S; Kanagalinghan, U; Nwokolo, N; Whitlock, G (London, UK)*
- P013 Attitudes towards pre-exposure prophylaxis against HIV infection among individuals seeking voluntary counseling and testing for HIV in Taiwan**
Chang, L; Liu, W; Wu, C; Lee, Y; Sun, H; Hung, C; Chang, S (Taipei, Taiwan)*
- P014 'Self-perceived' pre-exposure prophylaxis adherence and its relationship to self-reported 'actual adherence' among Thai men who have sex with men and transgender women**
Anand, T; Kerr, S; Apornpong, T; Nitpolprasert, C; Ananworanich, J; Phanuphak, P; Phanuphak, N (Bangkok, Thailand)*
-

*Indicates presenting author.

POSTER PRESENTATIONS (continued)


- P015 Polish infectious diseases physicians' attitudes and beliefs about pre-exposure prophylaxis for HIV prevention**
Kolodziej, J; Mikula, T; Wiercinska-Drapalo, A (Warsaw, Poland)*
-
- P016 Pre-exposure prophylaxis awareness in individuals accessing a non-occupational post-exposure prophylaxis (NPEP) program**
Peel, J; Lachowsky, N; Moore, D; Jabbari, S; Zhang, W; Guillemi, S; Harris, M; Grennan, T; Wong, J; Montessori, V; Ogilvie, G; Montaner, J; Hull, M (Vancouver, Canada)*
-
- P017 PrEP use in Lisbon while waiting for a policy**
Meireles, P; Rocha, M; Campos, M; Barros, H (Lisbon, Portugal)*
-
- P018 Increasing ART coverage and viral suppression are associated with a substantial decline in new HIV infections in the Austrian Tyrol**
Leierer, G; van Sighem, A; Sarceletti, M; Kitchen, M; Gisinger, M; Rappold, M; Ledergerber, B; Zangerle, R (Innsbruck, Austria)*
-
- P019 Implementation of isoniazid preventive therapy for people living with HIV in Northwestern Nigeria: integration challenges and issues**
Adepoju, A; Egesemba, G; Kangiwa, U; Igene, P (Birnin Kebbi, Nigeria)*
-
- P020 Cascade of care in TAK project: strong in right side, but weak in left side**
Kowalska, J; Shepherd, L; Ankiersztejn-Bartczak, M; Firlag-Burkacka, E; Horban, A; Mocroft, A (Warsaw, Poland)*

Treatment Strategies

- P021 Durability and tolerability of first-line combination including two NRTIs and RAL or ATV/r or DRV/r in patients enrolled in the ICONA Foundation cohort**
d'Arminio Monforte, A; Lorenzini, P; Cozzi-Lepri, A; Mussini, C; Castagna, A; Baldelli, F; Puoti, M; Mazzotta, F; Abrescia, N; Lo Caputo, S; Gianotti, N; Antinori, A; on behalf of the ICONA Foundation cohort (Milan, Italy)*
-
- P022 HIV-1 combinectin GSK3732394: a long-acting inhibitor with multiple modes of action**
Krystal, M; Wensel, D; Sun, Y; Davis, J; McDonagh, T; Li, Z; Zhang, S; Soars, M; Cockett, M (Wallingford, USA)*
-
- P023 Mono- and dual suppressive antiretroviral regimens in a real-life setting: the experience of Pitié Salpêtrière HIV Centre**
Caby, F; Agher, R; Tubiana, R; Blanc, C; Jaspard, M; Dudoit, Y; Calin, R; Calvez, V; Simon, A; Valantin, M; Katlama, C (Paris, France)*
-
- P024 Safety and antiviral effect of elpida (VM-1500), a novel NNRTI (+truvada) in treatment-naïve HIV-1-infected patients at 24–48 weeks of therapy**
Kravchenko, A; Orlova-Morozova, E; Nagimova, F; Kozirev, O; Shimonova, T; Bichko, V; Vostokova, N; Zozulya, O (Moscow, Russian Federation)*
-
- P025 The integrase strand transfer inhibitor bictegravir has a long integrase/DNA dissociation half-life**
White, K; Majka, A; Novikov, N; Miller, M; Tsiang, M (Foster City, USA)*
-
- P026 Durability and prescribing patterns of initial HIV regimens in treatment-naïve patients**
Eaton, E; Tamhane, A; Prajapati, G; Goodwin, B; Saag, M (Rahway, USA)*
-
- P027 Integrase inhibitor-based antiretroviral therapy in vulnerable populations**
Conway, B; Kiani, G; Shahi, R; Raycraft, T; Singh, A; Hakobyan, S; Alimohammadi, A (Vancouver, Canada)*

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P028 Inhibition of HIV-1 protease and plasmodium falciparum by a modified digold chloroquine derivative**
*Gama, N**; Kumar, K; Reader, J; Gordhan, B; Birkholtz, L; Kana, B; Darkwa, J; Meyer, D (Pretoria, South Africa)
-
- P029 Treatment failure of chronic HCV infection with the new direct-acting antivirals: experience of a Portuguese central hospital**
*Pereira, K**; Dias Grazina, S; Miranda, A; Baptista, T; Borges, F; Nina, J; Peres, S; Aldir, I; Campos, M; Antunes, I; Pereira, J; Ventura, F; Mansinho, K (Lisbon, Portugal)
-
- P031 Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations in routine care of HIV-infected children with diverse ethnic origin**
 *Soeria-Atmadja, S**; Österberg, E; Gustafsson, L; Dahl, M; Eriksen, J; Rubin, J; Navér, L (Stockholm, Sweden)
-
- P032 Relative bioavailability and food effect of a paediatric dispersible tablet formulation of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine (RPV)**
*Crauwels, H**; Goyvaerts, N; Vanveggel, S; Van Solingen, R (Beerse, Belgium)
-
- P033 Predictors of plasma HIV RNA suppression in a cohort of perinatally HIV-infected individuals**
*Contreras, G**; Rodriguez, G; Del Bianco, G; Perez, N; Benjamins, L; Murphy, J; Heresi, G (Houston, USA)
-
- P034 Characteristics and outcome of HIV-positive children internationally adopted in France**
*Lesens, O**; Blanche, S; Corbin, V; Jacomet, C (Clermont-Ferrand, France)
-
- P035 Efficacy of dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) fixed-dose combination (FDC) compared with ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in treatment-naïve women with HIV-1 infection (ARIA study): subgroup analyses**
 *Johnson, M**; Gatey, C; Manosuthi, W; Lazzarin, A; Podzamczar, D; Man, C; Aylott, A; Buchanan, A; Wynne, B; Vavro, C; Aboud, M; Smith, K (London, UK)
-
- P036 Sex and gender differences in rilpivirine-based ART: data from the HIV Center Frankfurt**
*Schüttfort, G**; Philipp, K; Brodt, H; de Leuw, P; Göpel, S; Herrmann, E; Khaykin, P; Stephan, C; Wolf, T; Haberl, A (Frankfurt am Main, Germany)
-
- P038 Treatment outcomes and co-morbidities in German female HIV-infected patients in 2015: a comparison to 2008 and to a male population**
*Roemer, K**; Usadel, S; Graefe, K; Steib-Bauert, M; Speer, M; Fischer, S; Hanhoff, N; Knecht, G (Cologne, Germany)
-
- P039 Discontinuation of first-line ART is associated with female sex and migration background: data from a German outpatient clinic**
*Bilinski, S**; De Leuw, P; Göpel, S; Khaykin, P; Schüttfort, G; Brodt, H; Wolf, T; Stephan, C; Herrmann, E; Haberl, A (Frankfurt, Germany)
-
- P040 Risk factors for late presentation over the last 6 years in Athens, Greece (2009–2015)**
*Spanos, A; Kavatha, D; Protopapas, K**; Siakalis, G; Argyropoulou, M; Moschopoulos, C; Antalis, E; Fragkou, P; Melachrinopoulos, N; Tsiodras, S; Antoniadou, A; Papadopoulos, A (Athens, Greece)
-
- P041 Late presenters: how do they look after ART nowadays?**
*Oliveira Paulo, C**; Duarte, F; Ruiz Pena, E; Guimarães, M; Correia Abreu, R; Jordao, S; Neves, I (Matosinhos, Portugal)
-
- P042 The utility of enfuvirtide revisited**
*Pinho, R**; Campoa, E; Faria, D; Santos, C; Arez, L (Portimão, Portugal)
-

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P043 Pre-existing HIV-1 integrase polymorphisms do not impact treatment response to elvitegravir-containing fixed-dose combination regimens in treatment-naïve patients**
Abram, M; Ram, R; White, K; Miller, M; Callebaut, C (Foster City, USA)*
-
- P044 Does ethnic origin influence timing, choice and response to first-line antiretroviral therapy in France?**
Gatey, C; Brun, A; Turpault, I; Sellier, P; Bouchaud, O; Patey, O; Garrat, V; Jeantils, V; Chabrol, A; Diamantis, S; Gregoire-Faucher, V; Froguel, E; Son, O; Lamy, S; Routier, C; Ait Mohand, H; Turner, L; Hamet, G; Delaugerre, C; Rozenbaum, W; Molina, J; and the COREVIH Ile de France (Paris, France)*
-
- P045 Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve Asian adults**
Oka, S; Chetchotisakd, P; Clarke, A; Supparatpinyo, K; Kiertiburanakul, S; Ryu, J; Piontkowsky, D; Guo, S; Nguyen-Cleary, T; Das, M; McCallister, S (Tokyo, Japan)*
-
- P046 Combining lopinavir/r with new ARV agents in ART-naïve HIV-infected patients: data from the German multicenter PROTEKT cohort**
Wolf, E; Hillenbrand, H; Baumgarten, A; Stephan, C; Lutz, T; Koeppe, S; Huelsenbeck, J (Wiesbaden, Germany)*
-
- P047 Outcome of antiretroviral regimens prescribed by following the regulations on combination antiretroviral therapy by Taiwan Centers for Disease Control**
Tsai, M; Yang, C; Zhang, J; Wu, P; Yang, S; Luo, Y; Chang, H; Lin, K; Sun, H; Hung, C (New Taipei City, Taiwan)*
-
- P048 Prescription pattern and determinants of dolutegravir use in an antiretroviral-naïve HIV-infected population in Italy: data from the ICONA Foundation cohort**
Antinori, A; Cozzi Lepri, A; Castagna, A; Lo Caputo, S; Mussini, C; Rusconi, S; Di Biagio, A; Marchetti, G; Nozza, S; Cingolani, A; De Luca, A; d'Arminio Monforte, A; on behalf of the ICONA Foundation cohort (Rome, Italy)*
-
- P049 The RESINA data support the individualized therapy based on primary resistance testing**
Knops, E; Schuelter, E; Luebke, N; Neumann-Fraune, M; Heger, E; Sierra-Aragon, S; Mueller, C; Oette, M; Faetkenheuer, G; Hower, M; Knechten, H; Schuebel, N; Esser, S; Scholten, S; Haeussinger, D; Kaiser, R; Jensen, B (Cologne, Germany)*
-
- P050 The acute/recent HIV infection cohort from Hospital Clinic, Barcelona: epidemiological trends and evolution from 1997 to 2015**
Nicolás Ocejo, D; Ambrosioni, J; Manzardo, C; Agüero, F; Mosquera, M; Parera, M; Sanchez-Palomino, S; Ligeró, C; Fernandez, E; de Lazzari, E; Plana, M; Gatell, J; Miró, J (Barcelona, Spain)*
-
- P051 Neurological involvement in patients with acute/recent HIV-1 infection**
Artigues, F; Ambrosioni, J; Nicolás, D; Peñafiel, J; Agüero, F; Manzardo, C; Mosquera, M; Sánchez-Palomino, S; de Lazzari, E; Marcos, M; Plana, M; Miro, J (Barcelona, Spain)*
-
- P052 Single-tablet regimen with elvitegravir, cobicistat, emtricitabine and tenofovir for the treatment of early HIV infection**
Teira, R; Galindo, M; Montero, M; Portilla, R; Ferrer, A; Martinez, E (Torrelavega, Spain)*
-
- P053 Comparison of (TDF+FTC) associated with either darunavir/ritonavir+raltegravir or dolutegravir: virological efficacy of two different treatment strategies for primary HIV infection (PHI)**
Pinnetti, C; Abbate, I; Lorenzini, P; Orchi, N; Gori, C; Amendola, A; Libertone, R; Rozera, G; Plazzi, M; Fabbri, G; Capobianchi, M; Antinori, A; Ammassari, A (Rome, Italy)*

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P054 Safety and efficacy of dolutegravir plus rilpivirine (DTG/RPV) in treatment-experienced HIV-infected patients: preliminary results at 24 weeks of the DORIVIR study**
*Palacios, R**; Mayorga, M; González-Domenech, C; Hidalgo-Tenorio, C; Gálvez, C; Muñoz-Medina, L; de la Torre, J; Lozano, A; Castaño, M; Omar, M; Santos, J (Málaga, Spain)
-
- P055 Efficacy, safety and patient-reported outcomes from treatment-experienced subjects in routine clinical practice switching to EVG/COBI/FTC/TAF (Genvoya®): the German TAFNES cohort**
*Schleenvoigt, B**; Jessen, H; Waizmann, M; Pauli, R; Rieke, A; Postel, N; Heuchel, T; Schulz, C; Mueller, M; Moll, A; Stephan, C; Spinner, C; Haubrich, R; Heinzkill, M; Wieszner, C; Stellbrink, H (Jena, Germany)
-
- P056 Frailty improves in both young and old HIV patients undergoing atazanavir-based regimens**
*Guaraldi, G**; Malagoli, A; Dolci, G; Carli, F; Menozzi, M; Santoro, A; Zona, S; Mussini, C (Modena, Italy)
-
- P057 High-level HIV drug resistance mutations in patients with unsuppressed viral load from Northern South Africa**
*Etta, E**; Manhaeve, C; McGonigle, K; Rekosh, D; Hammarskjold, M; Tebit, D; Bessong, P (Charlottesville, USA)
-
- P058 Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT)**
*Marshall, N; McNulty, M; Smith, C; Swaden, L; Burns, F; Orkin, C** (London, UK)
-
- P059 Long-term virological outcomes of replacing zidovudine or stavudine with tenofovir in the absence of routine virological monitoring in Kumasi, Ghana**
*Villa, G**; Phillips, R; Smith, C; Stockdale, A; Beloukas, A; Appiah, L; Chadwick, D; Ruggiero, A; Sarfo, F; Geretti, A (Liverpool, UK)
-
- P060 Non-adherence in HIV patients is caused by specific reasons: results from the German adherence cohort study**
*Boretzki, J; Wiese, C; Oldenbuettel, C; Krznic, I; Meurer, A; Zink, A; Lersch, C; Balogh, A; Wolf, E; Spinner, C** (Munich, Germany)
-
- P061 Prevalence of HIV virological failure in a multidisciplinary centre treating high-risk vulnerable populations**
*Alimohammadi, A**; Raycraft, T; Kiani, G; Shahi, R; Singh, A; Hakobyan, S; Conway, B (Vancouver, Canada)
-
- P062 Methadone maintenance treatment and efficiency of ART in HIV-positive injecting drug users in the Ukraine**
*Zhyvytsia, D**; Kazeka, V (Zaporizhia, Ukraine)
-
- P063 Community pharmacy dispensed ART alongside opiate replacement therapy in Glasgow's HIV outbreak**
*Peters, S; Brown, K**; Laird, A; Gillespie, R; Thomson, D; Milosevic, C (Glasgow, UK)
-
- P064 HIV testing and care in prisoners: the first year results of opt-out BBV testing in Glasgow, UK**
*Peters, S**; Bissett, B; Cassells, Y; Paton, J; Aitken, C (Glasgow, UK)
-
- P065 Correlates of HIV virological non-suppression at a tertiary clinic**
*Singh, A**; Raycraft, T; Alimohammadi, A; Kiani, G; Shahi, R; Conway, B (Vancouver, Canada)
-

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P066** **The effect of relationship status and housing stability on adherence to combination antiretroviral therapy among people living with HIV who use illicit drugs in British Columbia, Canada**
*Singh, A**; Salters, K; Parashar, S; Puskas, C; Wang, L; Montaner, J; Hogg, R; Samji, H (Burnaby, Canada)
-
- P067** **HIV support group within a multidisciplinary healthcare delivery model as a treatment strategy for people who inject drugs**
*Shahi, R**; Kiani, G; Alimohammadi, A; Raycraft, T; Singh, A; Hakobyan, S; Conway, B (Vancouver, Canada)
-
- P068** **Adherence to cART and low-level viremia in a large single-center clinical cohort**
*Maggiolo, F**; Di Filippo, E; Callegaro, A; Colombo, G; Di Matteo, S; Valenti, D; Rizzi, M (Bergamo, Italy)
-
- P069** **Developing a patient-reported outcome measure (PRO) for HIV care on perceived barriers to antiretroviral adherence: assessing the needs of HIV clinicians through typological analysis**
*Toupin, I**; Engler, K; Lessard, D; Lènarç, A; Raffi, F; Spire, B; Lebouché, B (Montreal, Canada)
-
- P070** **Patient acceptance of a web-linked smartphone app to assess treatment compliance in HIV-infected subjects: a pilot study**
*Sala-Piñol, F**; Andreu-Crespo, A; Llibre, J; Coll, J; Grasa, J; Calvet, A; Clotet, B; Bonafont-Pujol, X (Barcelona, Spain)
-
- P071** **The moderating role of treatment engagement on the relationship between neurocognitive impairment and antiretroviral treatment (ART) adherence**
*Shrestha, R**; Karki, P; Huedo-Medina, T; Copenhaver, M (Farmington, USA)
-
- P072** **Real-world persistence and outcomes for HIV-1 treatment: single- versus multiple-tablet regimen comparison**
*Sweet, D; Budd, D**; Cohen, J (Foster City, USA)
-
- P073** **Factors influencing clinicians' choices of ARVs in the USA**
*Hahn, R; Goodwin, B; Hogue, S; Murray, M**; Davis, K (Brentford, UK)
-
- P075** **MATH study: migrants adherence to therapy at an HIV outpatient clinic**
*Rodrigues, C**; Martins, Y; Caixas, U; Lampreia, F; Germano, I (Lisbon, Portugal)
-
- P076** **Predictors of retention to care among HIV-infected patients in Northern Greece**
*Tsachouridou, O**; Christaki, E; Skoura, L; Rana, A; Zempekakis, P; Metallidis, S (Thessaloniki, Greece)
-
- P077** **Treatment of HIV and acute myeloid leukemia by allogeneic CCR5-d32 blood stem cell transplantation**
*Knops, E**; Kobbe, G; Kaiser, R; Luebke, N; Dunay, G; Wensing, A; Martinez-Picado, J; Nijhuis, M; Fischer, J; Huettig, F; Haas, R; Haeussinger, D; Jensen, B (Cologne, Germany)
-
- P078** **Differential efficacy of ABX464 and its primary metabolite ABX464-NGlc on HIV replication in human PBMCs and macrophages: implications for treatment strategies to eliminate virus reservoirs**
*Scherrer, D**; Steens, J; Gineste, P; Campos, N; Garcel, A; Schlaefper, E; Speck, R; Tazi, J; Ehrlich, H (Paris, France)
-
- P079** **Development of methods for in vitro reactivation of latent reservoir of HIV-1 infection in patients under suppressive HAART**
*Jadav, G** (Siena, Italy)
-

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P080** **Dual regimen with dolutegravir and lamivudine maintains virologic suppression even in heavily treatment-experienced HIV-infected patients: 48-week results from a pilot study (DOLULAM)**
Reynes, J^{*}; Meftah, N; Montes, B (Montpellier, France)*
-
- P081** **Efficacy of antiretroviral drugs during intermittent maintenance treatment with a 4-days-a-week regimen despite low plasma concentrations (ANRS 162-4D trial)**
Alvarez, J^{*}; De Truchis, P; Abe, E; Assoumou, L; Landman, R; Mathez, D; Amat, K; Katlama, C; Girard, P; Le Du, D; Duracinsky, M; Costagliola, D; Bellet, J; Perronne, C (Garches, France)*
-
- P082** **Dual therapy with non-boosted atazanavir plus lamivudine is an effective simplification strategy for virologically stable patients with HIV**
Pasquau, J; de Jesús, S^{*}; García-Vallecillos, C; Hidalgo-Tenorio, C (Granada, Spain)*
-
- P083** **Lamivudine + dolutegravir as simplification strategy in patients with suppressed HIV RNA**
Maggiolo, F^{*}; Gulminetti, R; Mussini, C; Pagnucco, L; Digaetano, M; Benatti, S; Valenti, D; Ripamonti, D (Bergamo, Italy)*
-
- P084** **In monotherapy, darunavir/cobicistat demonstrates equivalence to darunavir/ritonavir, and in selected patients is as effective as bitherapies or triple therapies**
Pasquau, J; García-Vallecillos, C; Cruces-Moreno, M; de Jesus, S^{*}; Fatoul del Pino, G; Hidalgo-Tenorio, C; Vinuesa-García, D; López-Ruz, M; Hernández-Quero, J (Granada, Spain)*
-
- P085** **Darunavir/cobicistat as antiretroviral treatment simplification strategy in patients with stable monotherapy with ritonavir-boosted protease inhibitors in the clinical setting**
Santos, J^{*}; Peláez Ibañez, P; Bravo, I; Llibre, J; Paredes, R; Clotet, B; Moltó, J (Barcelona, Spain)*
-
- P086** **3-year efficacy and durability of simplification to a single-tablet regimen (STR): a comparison between coformulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir**
Gagliardini, R^{*}; Bandera, A; Zaccarelli, M; Sterrantino, G; Latini, A; D'Avino, A; Picarelli, C; Lapadula, G; Antinori, A; Cauda, R; De Luca, A; Gori, A; Di Giambenedetto, S; Fabbiani, M (Rome, Italy)*
-
- P087** **Efficacy and safety of switch from DRV/r to DRV/COBI in HIV monotherapy**
Gutiérrez Liarte, Á^{*}; Gómez Berrocal, A; De Miguel Buckley, R; Sanz Sanz, J (Madrid, Spain)*
-
- P088** **Efficacy and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced HIV patients**
Pasquau, J; de Jesus, S^{*}; Hidalgo-Tenorio, C; Arazo, P; Crusells, M; Rios, M; Lozano, F; de la Torre, J; Tornero, C; García-Vallecillos, C; Verdejo, G; Palacios, Z; Samperiz, G; Galindo, M; Terron, J; Garcia-Deltoro, M (Granada, Spain)*
-
- P089** **Simplification to dual protease inhibitor (PI)-, integrase strand transfer inhibitor (INSTI)- and non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based less drugs regimens in treatment-experienced HIV-1-infected patients**
Mastroianni, A^{*}; Briganti, E; Allegrini, F; Grosso, C; Brighi, S; Ravaglia, G; Pieraccini, F; Cancellieri, C (Forlì, Italy)*
-
- P090** **Dolutegravir and unboosted atazanavir: a dual NRTI- and booster-free antiretroviral regimen simplification in HIV-1-infected patients with viral suppression**
Riva, A^{*}; Poli, A; Rusconi, S; Bonora, S; Cattelan, A; Quiros Roldan, E; Ferrara, M; Spagnuolo, V; Pagnucco, L; Cavinato, S; Cattaneo, D; Gulminetti, R; Castagna, A (Milan, Italy)*
-
- P091** **Treatment of HIV-positive patients with lamivudine plus boosted protease inhibitor in a real-world setting**
Cheng, C^{*}; Cheng, S; Chang, S; Lin, M; Ku, S; Shieh, H; Sun, N (Taoyuan City, Taiwan)*
-

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P092 Effectiveness and convenience of ATV/r+3TC dual therapy regimen in a real-life cohort of HIV-infected patients: 48-week follow-up**
Ferrara, S; Tartaglia, A; Sica, S; Santantonio, T (Foggia, Italy)*
-
- P093 Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) versus emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent**

Post, F; Yazdanpanah, Y; Schembri, G; Lazzarin, A; Reynes, J; Maggiolo, F; Yan, M; Abram, M; Tran-Muchowski, C; Cheng, A; Rhee, M (London, UK)*
-
- P094 Population pharmacokinetics (PK) of dolutegravir (DTG) alone and following treatment switch**

Dickinson, L; Bracchi, M; Elliot, E; Else, L; Khoo, S; Back, D; Nelson, M; Boffito, M (Liverpool, UK)*
-
- P095 Virological response of HIV-infected patients virologically suppressed switching to a DTG-based regimen in an observational cohort based on the genotypic susceptibility score**
Charpentier, C; Peytavin, G; Joly, V; Cabras, O; Perrier, M; Lê, M; Phung, B; Yazdanpanah, Y; Descamps, D; Landman, R (Paris, France)*
-
- P096 Evaluation of virologic efficacy and economic savings in a Portuguese hospital after splitting the single-tablet regimen EFV/FTC/TDF (Atripla®) to an equivalent double-tablet regimen (efavirenz+Truvada®)**
Guimarães, M; Vaz Pinto, I; Santos, C; Alves, S (Cascais, Portugal)*
-
- P097 Dolutegravir plus ritonavir-boosted darunavir in highly cART-experienced subjects: an observational cohort**
Capetti, A; Sterrantino, G; Cossu, M; Cenderello, G; Rusconi, S; Cima, S; Baldin, G; Cattelan, A; De Socio, G; Riccardi, N; Orofino, G; Celesia, B; Niero, F; Sasset, L (Milan, Italy)*
-
- P098 A retrospective analysis to evaluate and compare the efficacy of switching to stribild fixed-dose combination in virologically-suppressed HIV-1-infected adults with or without the archived NRTI-resistance mutation M184V/I**
Silebi, V (Miami, USA)*
-
- P099 Dolutegravir plus rilpivirine in cART-experienced subjects: an observational cohort**
Capetti, A; Sterrantino, G; Cossu, M; De Socio, G; Di Giambenedetto, S; Celesia, B; Argentero, B; Di Biagio, A; Orofino, G; Barbarini, G; Rizzardini, G (Milan, Italy)*
-
- P100 Switching to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): effects on T-cell compartment and HIV reservoirs**
Merlini, E; Cazzaniga, F; Casabianca, A; Orlandi, C; Ancona, G; Cogliandro, V; Tincati, C; Bini, T; Magnani, M; d'Arminio Monforte, A; Marchetti, G (Milan, Italy)
-
- P101 Reducing pill burden is more durable than reducing drug burden as strategy of HIV treatment simplification**
Zaccarelli, M; Lorenzini, P; Gianotti, N; Rusconi, S; Viale, P; Chirianni, A; Sighinolfi, L; Parruti, G; d'Arminio Monforte, A; Antinori, A; on behalf of the ICONA Foundation cohort (Rome, Italy)*
-
- P102 Efficacy and safety of switch to DRV/cobicistat in patients who are virologically suppressed with treatment regimens containing DRV/r**
de la Fuente Moral, S; Díaz de Santiago, A; Folguera, C; De Mendoza Fernandez, C; Angel-Moreno Maroto, A (Madrid, Spain)*
-
- P103 Confirmed efficacy and safety of dual therapy based on lamivudine plus a ritonavir-boosted protease inhibitor in the clinical setting**
Fontecha-Ortega, M; Muñoz-Mendoza, V; Gómez, C; Sánchez-Conde, M; Rodríguez, M; Vivancos, M; Casado, J (Getafe, Spain)*

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P104 Preferred regimens and reasons for switches in HIV-positive individuals in the German HIV-HEART cohort study over 30 years of antiretroviral treatment evolution**
Holzendorf, V; Esser, S; on behalf of the HIV-HEART Study Group (Essen, Germany)*
-
- P105 Drug concentrations, adherence, patient-reported symptoms and health-related quality of life in HIV-infected, virologically controlled patients switching to maraviroc+darunavir/ritonavir or continuing the previous triple therapy: sub-studies from the randomized GUSTA trial**
Rossetti, B; Gagliardini, R; Lisi, L; Masini, M; Lamonica, S; Vignale, F; Sterrantino, G; Orofino, G; Colafigli, M; Latini, A; Tosti, A; Rusconi, S; Trezzi, M; D'Avino, A; Grima, P; Mezzaroma, I; Di Biagio, A; Navarra, P; Di Giambenedetto, S; De Luca, A (Siena, Italy)*
-
- P106 A comparison between tenofovir/emtricitabine/elvitegravir/cobicistat and dolutegravir-based three-drug regimens as switch strategies for virologically controlled, HIV-infected patients**
Baldin, G; Borghetti, A; Capetti, A; Sterrantino, G; Rusconi, S; Latini, A; Giacometti, A; Cossu, M; Colafigli, M; Micale, M; Veloci, S; Lombardi, F; De Marco, R; Emiliozzi, A; De Luca, A; Di Giambenedetto, S; Madeddu, G (Rome, Italy)*
-
- P107 Durability, metabolic impact and efficacy of switching from a PI/r- to an INI-containing regimen in a monocentric cohort of drug-experienced HIV-positive subjects**
Rusconi, S; Oreni, L; Formenti, T; Giacomelli, A; Di Cristo, V; Lupo, A; Colella, E; Franzetti, M; Ridolfo, A; Galli, M (Milan, Italy)*
-
- P108 Switch to dolutegravir in HIV patients responding to a first-line antiretroviral treatment: 48 weeks results**
Tau, L; Ziv-Baran, T; Cohen-Poradosu, R; Leshno, A; Alon, D; Shasha, D; Rapaport, S; Wasserman, A; Finn, T; Katchman, E; Hassin, D; Yust, I; Brofman, T; Avidor, B; Turner, D (Tel Aviv, Israel)*
-
- P109 Antiretroviral treatment received by patients in the Spanish VACH cohort: change over time**
Roca, B (Castellon, Spain)*
-
- P110 The RAL-AGE study: benefits of switching to raltegravir-containing regimens in the older population**
Pavone, P; Giustini, N; d'Ettorre, G; Serafino, S; Schietroma, I; Corano Scheri, G; Mezzaroma, I; Andreotti, M; Mastrangelo, A; Mastroianni, C; Vullo, V (Rome, Italy)*
-
- P111 Characteristics and satisfaction survey in patients switching to darunavir/cobicistat (DRV/c)**
Vivancos-Gallego, M; Moreno, A; Quereda, C; Casado, J; Gomez Ayerbe, C; Sanchez-Conde, M; Del Campo, S; Moreno, S; Perez Elias, M (Madrid, Spain)*
-
- P112 Short-term safety and tolerability of switch of backbone antiretroviral agents to coformulated tenofovir disoproxil fumarate/emtricitabine in HIV-positive Taiwanese patients**
Chang, H; Wu, P; Zhang, J; Yang, S; Luo, Y; Liu, W; Sun, H; Hung, C; Chang, S (Taipei, Taiwan)*
-
- P113 Optimizing viral load testing to improve quality of care and client retention for PLHIVs in a HIV clinic in Northern Nigeria: impact and experiences**
Nwabueze, E; Ndulue, N; Egesimba, G; Makumbi, M; Kpamor, Z; Okechukwu, E; Kolin, J (Abuja, Nigeria)*
-
- P114 Knowing the epidemic is the best way to define diagnosis and treatment strategies to reach the 90-90-90 goals: the experience of Portugal using the ECDC HIV modelling tool**
Diniz, A; Loff, J; Cortes-Martins, H (Lisbon, Portugal)*
-
- P115 Drug retention time: a real-life Swedish nationwide cohort study on InfCareHIV 2009–2014**
Hägglom, A; Lindbäck, S; Gisslén, M; Flamholc, L; Hejdeman, B; Palmborg, A; Leval, A; Herweijer, E; Valgardsson, S; Svedhem, V (Gävle, Sweden)*
-

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P116 Discontinuation of dolutegravir (DTG)-based regimens in clinical practice**
*Vivancos-Gallego, M**; Moreno, A; Perez-Elias, M; Gomez Ayerbe, C; Casado, J; Quereda, C; Sanchez-Conde, M; Serrano Villar, S; Dronda, F; Navas, E; Rodriguez, M; Moreno, S (Madrid, Spain)
-
- P117 Dolutegravir (DTG) monotherapy treatment de-escalation in virological controlled, pre-treated HIV patients: results from the DoluMono cohort study**
*Oldenbüttel, C**; Wolf, E; Ritter, A; Noe, S; Heldwein, S; Pascucci, R; Wiese, C; von Krosigk, A; Jägel-Guedes, E; Jäger, H; Balogh, A; Kögl, C; Spinner, C (Munich, Germany)
-
- P118 Outcomes of cabotegravir (CAB) treatment in HIV-1 ART-naïve patients with chronic or acute hepatitis C virus (HCV) co-infection: data from the phase IIb programme**
*Thiagarajah, S**; Dorey, D; Huang, J; Roberts, G; Stancil, B; Margolis, D (London, UK)
-
- P119 Antiretroviral treatment patterns in the USA: an analysis of real-world data**
*Goodwin, B**; Tran, J; White, J; Mao, J; Cao, F (Whitehouse Station, USA)
-
- P120 Selected antiretroviral treatment option is associated with virological success: multicentre data from Poland**
*Parczewski, M; Leszczyszyn-Pynka, M**; Witor, A; Muller, K; Szymczak, A; Gaşiorowski, J; Bociaga-Jasik, M; Skwara, P; Grzeszczuk, A; Jabłonowska, E; Wójcik-Cichy, K; Kamerys, J; Bielec, D; Stempkowska, J; Kocbach, A; Błudzin, W (Szczecin, Poland)
-
- P121 Much less treatment modification with recently approved drugs: the Austrian HIV cohort study**
*Rappold, M**; Rieger, A; Schmied, B; Sarcletti, M; Geit, M; Haas, B; Taylor, N; Kanatschnig, M; Leierer, G; Ledergerber, B; Zangerle, R (Innsbruck, Austria)
-
- P122 Integrase strand transfer inhibitors in the treatment of HIV-2 infection: report of 39 patients**
*Sequeira, F**; Grazina, S; Alves, J; Peres, S; Borges, F; Miranda, A; Aldir, I; Mansinho, K (Penafiel, Portugal)
-
- P123 Effect of probiotics on inflammation in the gut in HIV-infected individuals evaluated using PET/MR**
*Arnbjerg, C; Pedersen, K; Jespersen, S; Fischer, B; Johannesen, H; Fallentin, E; Hansen, A; Kjær, A; Trøseid, M; Dam Nielsen, S** (Copenhagen, Denmark)
-
- P124 Starting antiretroviral therapy for HIV at the first visit and early after inclusion into care: an observational study**
*Begovac, J; Zekan, Š**; Zidovec Lepej, S; Lukas, D (Zagreb, Croatia)
-
- P125 Psychometric evaluation of a new individualised condition-specific quality of life questionnaire for HIV (HIVDQoL)**
*Romaine, J; Murray, M; Bradley, C** (London, UK)
-
- P126 Individualized NRTI-sparing antiretroviral regimens in a real-world clinical setting maintain virologic efficacy with significant cost reduction**
*Arponen, S**; Gimeno-García, A; Montero-Hernández, C; Esteva, L; Blasco, M; Gaspar-García, E; García-Navarro, M (Torrejón de Ardoz, Spain)
-
- P127 A retrospective analysis of time to non-detectable HIV viral load in fixed dose combination anti-retroviral therapy in HIV-1-infected patients enrolled in the Mater Misericordiae University Hospital Infectious Diseases (MMUH-ID) cohort**
*Grant-Freemantle, M; Mallon, P; McCombe, G; Macken, A; Tinago, W; Avramovic, G; O'Halloran, J; Cotter, A; Sheehan, G; Lambert, J** (Dublin, Ireland)

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P128 Antiretroviral treatment changes due to treatment of hepatitis C with direct-acting antivirals in co-infected patients**
*Ferrero, O**; Ibarra, S; López-Azkarreta, I; de la Peña, M; López-Martínez, M; Baraia-Etxaburu, J; López de Munain, J; Cámara, M; Zubero, Z; Muñoz, J (Bilbao, Spain)
-
- P129 The use of protease inhibitors in patients with blips is associated with virologic failure**
*Sanchez-Brown, E**; Soto-Ramírez, L (Mexico City, Mexico)
-
- P130 Baseline characteristics of the TRIUMPH and DOL-ART cohorts: use of Triumeq® (DTG/ABC/3TC) or other DTG-based ART in routine clinical care in Germany**
*Heuchel, T**; Postel, N; Bickel, M; Brust, J; Scholten, S; Schulz, C; Stephan, C; Bohr, U; Hillenbrand, H; Glaunsinger, T; Stoehr, A; Westermayer, B; Wigger, A; Lüftenegger, D; Walli, R (Chemnitz, Germany)
-
- P131 Long-term use of darunavir/r QD containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV patients**
*De Wit, S**; Florence, E; Vandekerckhove, L; Vandercam, B; Goffard, J; Van Wijngaerden, E; Moutschen, M; Demeester, R; Piryns, H; Thilakarathne, P (Brussels, Belgium)
-
- P132 Assessment of the results at 96 weeks of a multicentric Portuguese cohort of patients treated with emtricitabine/tenofovir/rilpivirine**
*Almeida, F; Sequeira, F; Casella, M; Mota, M; Serrão, R; Mesquita, M; Goes, A; Teixeira, T; Piñeiro, C** (Porto, Portugal)
-
- P133 The DOL-ART cohort: providing evidence from real-world data – use of dolutegravir-based regimens in routine clinical care in Germany**
*Postel, N**; Mueller, M; Wyen, C; Brust, J; Stoehr, A; Glaunsinger, T; Scholten, S; Rausch, M; Westermayer, B; Herrmann, M; Walli, R (Munich, Germany)
-
- P134 First Canadian HIV+/HIV+ kidney transplantation and first results of the prospective cohort of solid organ transplantation for HIV individuals of Centre Hospitalier de l'Université de Montréal**
*Ambaraghassi, G**; Cardinal, H; Corsilli, D; Fortin, C; Fortin, M; Malaise, J; Martel-Laferrrière, V; Pâquet, M; Rouleau, D (Montréal, Canada)
-
- P135 Why do HIV/AIDS patients fail? Incidence, causes, demographic, immunologic and clinical characteristics of HIV patients who fail to achieve complete virologic suppression**
*Elbirt, D**; Inberg, Y; Mahlab-Guri, K; Asher, I; Bezalel-Rosenberg, S; Burke, M; Sthoeger, Z (Rehovot, Israel)
-
- P136 Hepatic safety during treatment with darunavir-based regimens in an Italian observational study**
*Antinori, A; Gori, A; Cauda, R; Orofino, G; Di Sora, F; Grossi, P; Mineo, M; Airoldi, G; Mancusi, D**; Termini, R (Cologno Monzese, Italy)
-
- P137 Long-term use of darunavir/r QD monotherapy in daily practice: retrospective observational cohort data of 111 HIV patients in Belgium**
*De Wit, S**; Florence, E; Vandekerckhove, L; Vandercam, B; Goffard, J; Van Wijngaerden, E; Moutschen, M; Demeester, R; Piryns, H; Thilakarathne, P (Brussels, Belgium)
-
- P138 Development of a contemporary symptom diary for patients with HIV**
*Markowitz, J**; Knoble, N; Arnould, B; Wu, A (Boston, USA)
-
- P139 A moderated mediation model of HIV-related stigma, depression and social support on health-related quality of life among incarcerated Malaysian men with HIV and opioid dependence**
*Shrestha, R**; Copenhaver, M; Altice, F (Farmington, USA)
-

*Indicates presenting author.

P140 The DRIVER study: asymptomatic STI systematic screening versus targeted screening according to STI risk factors in a cohort of outpatients HIV-infected MSM seen in France: phase 1 results
Fouere, S; Dimi, S; Timsit, J; Lalanne, C; Chassany, O; Duracinsky, M; Farfour, E; Majerholm, C; Zucman, D (Suresnes, France)*

P141 Metabolic safety during treatment with darunavir-based regimens in an Italian observational study
Antinori, A; Di Perri, G; Meraviglia, P; Angioni, G; Chirianni, A; Sterrantino, G; Quirino, T; Airoidi, G; Mancusi, D; Termini, R (Cologno Monzese, Italy)*

Opportunistic Infections

P142 Low rifampicin and isoniazid concentrations are associated with delayed sputum conversion in HIV-positive patients co-infected with tuberculosis in Uganda

Sekaggya, C; Ledergerber, B; von Braun, A; Lamorde, M; Buzibye, A; Eberhard, N; Scherrer, A; Nakijoba, R; Müller, D; Henning, L; Gutteck, U; Corti, N; Musaaazi, J; Kanya, M; Castelnuovo, B; Kambugu, A; Fehr, J (Kampala, Uganda)*

P143 Isoniazid preventive therapy is highly cost-effective among TB/HIV co-infected patients in Uganda
Wiltshire, C; Kuznik, A; Lamorde, M (Kampala, Uganda)*

P144 Predicting the in-hospital mortality in tuberculous meningitis
Jipa, R; Manea, E; Olaru, I; Merisor, S; Niculae, C; Hristea, A (Bucharest, Romania)*

P145 Tuberculosis infection in HIV patients in a Portuguese population
Maio, A; Coutinho, D; Nunes, S; Velez, J; Freitas, F; Oliveira, C (Aveiro, Portugal)*

P147 Use of dolutegravir in combination with rifampicin-based TB therapy in HIV/TB co-infected patients: real-world experience from Leeds, UK
Cevik, M; Vincent, R; McGann, H (Edinburgh, UK)*

P148 The practice and value of interferon gamma release assay testing for latent tuberculosis infection in people living with HIV: a retrospective review of patients at Leeds Teaching Hospitals Trust
Baggott, A; Cevik, M; McGann, H (Leeds, UK)*

P149 The global burden of AIDS in tuberculosis-infected patients and related financial aspects
Sargazi, A; Sepehri, Z; Nadakkavukaran Jim, P; Sargazi, A (Zabol, Iran)*

P150 Incidence and survival in HIV-infected patients with central nervous system opportunistic infections in the cART era: a 10-year Romanian single-center experience
Oprea, C; Ianache, I; Popa, I; Ene, L; Radoi, R; Tardei, G; Ungureanu, E; Erscoiu, S; Ceausu, E; Calistru, P (Bucharest, Romania)*

P151 In spite of international guidelines, vaccine coverage of HIV-infected patients remains low
Gagneux-Brunon, A; Frésard, A; Detoc, M; Charrière, E; Ronat, V; Lucht, F; Botelho-Nevers, E (Saint-Etienne, France)*

P152 Does syphilis impact on HIV infection when both diagnoses are concomitant?
Palacios, R; González-Domenech, C; Antequera, I; Ruiz-Morales, J; Nuño, E; Clavijo, E; Márquez, M; Santos, J (Málaga, Spain)*

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

Co-morbidities and Complications of Disease and/or Treatment

- P153** **Health-related costs in chronic HIV infection: a case-control study versus general population using a claims-based approach in Germany**
 Wolf, E*; Christensen, S (Munich, Germany)
- P154** **Ageing and the evolution of co-morbidities among HIV patients in the EuroSIDA cohort**
 Lopes, S*; Kirk, O; Lundgren, J; Laut, K; Edwards, S; Duvivier, C; Stephan, C; Sambatakou, H; Maciejewska, K; Aragão, F; Mocroft, A (London, UK)
- P155** **Future challenges for clinical care of an ageing population infected with HIV: a 'geriatric HIV' modelling study**
 De Francesco, D*; Malagoli, A; Theou, O; Zona, S; Carli, F; Dolci, G; Mussini, C; Kirkland, S; Mussi, C; Cesari, M; Rockwood, K; Guaraldi, G (London, UK)
- P156** **Quantifying the future clinical burden of an ageing HIV-positive population in Italy: a mathematical modelling study**
 Smit, M*; Cassidy, R; Cozzi-Lepri, A; Girardi, E; Mammone, A; Antinori, A; Angarano, G; Bai, F; Rusconi, S; Magnani, G; d'Arminio Monforte, A; Hallett, T (London, UK)
- P157** **Quantifying the future clinical burden of an ageing HIV-positive population in the USA: a mathematical modelling study**
Smit, M*; Cassidy, R; Hallett, T (London, UK)
- P158** **Silver champions from the GEPO cohort: a case control study of people between 65 and 75 years old and above 75 years of age addressing co-morbidities, multimorbidity and polypharmacy**
Guaraldi, G*; Malagoli, A; Dolci, G; Calcagno, A; Mussi, C; Celesia, B; Carli, F; Piconi, S; De Socio, G; Cattelan, A; Orofino, G; Riva, A; Morena, V; Focà, E; Nozza, S; Bugliosi, E; Di Perri, G (Modena, Italy)
- P159** **Co-morbidity in chronic HIV infection: a case-control study in Germany using health insurance claims data**
Christensen, S*; Wolf, E (Munich, Germany)
- P160** **Burden and determinants of frailty in a cohort of asymptomatic HIV ART-suppressed subjects without known co-morbidities**
Vita, S*; Lichtner, M; Rossi, R; Pozzetto, I; Tosato, C; Marocco, R; Zuccalà, P; Mascia, C; Campagna, M; d'Ettore, G; Turriziani, O; Falasca, F; Ajassa, C; Mastroianni, C; Vincenzo, V (Rome, Italy)
- P161** **Current models of care for the management of HIV patients with co-morbidities in England: a survey**
Youssef, E*; Cooper, V; Nixon, E; Vera, J; Fisher, M; Wright, J (Brighton, UK)
- P162** **The HIV patient profile in 2013 and 2003: results from the Greek AMACS cohort**
Pantazis, N*; Chini, M; Antoniadou, A; Sambatakou, H; Skoutelis, A; Gargalianos, P; Pappas, V; Gogos, C; Chryso, G; Psychogiou, M; Sipsas, N; Katsarou, O; Periklis, P; Touloumi, G (Athens, Greece)
- P163** **Antiretroviral therapy in Italian geriatric patients living with HIV/AIDS: analysis of GEPO cohort**
Nozza, S*; Malagoli, A; Dolci, G; Calcagno, A; Mussi, C; Celesia, B; Carli, F; Piconi, S; De Socio, G; Cattelan, A; Orofino, G; Riva, A; Morena, V; Focà, E; Bugliosi, E; Di Perri, G; Guaraldi, G (Milan, Italy)
- P164** **CD4/CD8 ratio matters to age-related health outcomes in HIV-infected patients with co-morbidities, frailty and disability**
Menozi, M*; Domingues da Silva, A; Malagoli, A; Dolci, G; Santoro, A; Carli, F; Mussini, C; Guaraldi, G (Modena, Italy)

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P165 Mortality rates and excess mortality among HIV-positive persons according to age in Spain, 2004–2014**
Alejos, B;* Hernando, V; Viciano, P; Montero, M; Berenguer, J; Rivero, M; Asensi, V; Garcia-Fraile, L; Gutierrez, F; Moreno, S; CoRIS cohort (Madrid, Spain)
-
- P166 Changes in the prevalence of cardiovascular, renal and bone co-morbidities and related risk factors in HIV-infected patients in the Spanish VACH cohort: a cross-sectional study in 2010 and 2014**
Teira, R;* Suarez-Lozano, I; Galindo, M; Montero, M; Geijo, P; Muñoz-Sanz, A; Martinez, E; Domingo, P; Lozano, F; Viciano, P; de la Fuente, B; Roca, B; Estrada, V; Muñoz-Sanchez, P; Vach, S (Torrelavega, Spain)
-
- P167 Epidemiologic ‘snapshot’ of the HIV-positive population in Belgium, 2014–2016**
Callens, S; De Wit, S; Wyndham-Thomas, C; Goffard, J; Moutschen, M; Meuris, C; van den Bulcke, C; Fombellida, K; del Forge, M; Razavi, H; Gunter, J* (Lafayette, USA)
-
- P168 From HIV diagnosis to viral suppression in a cohort of older patients**
Kundro, M;* Vilorio, G; Toibaro, J; Losso, M (Buenos Aires, Argentina)
-
- P169 The relative impact of antiretroviral drugs and baseline immune status on bone quality in HIV-positive subjects: results from the HIV UPBEAT cohort**
 *McGinty, T*;* Cotter, A; Sabin, C; Lambert, J; Sheehan, G; Macken, A; Kavanagh, E; Compston, J; Mallon, P (Dublin, Ireland)
-
- P170 Bone outcomes with EFV + TDF/FTC versus other TDF-containing antiretroviral regimens among HIV-infected veterans: a US national study**
LaFleur, J; Bress, A; Myers, J*; Rosenblatt, L; Crook, J; Nyman, H; Bedimo, R; Tebas, P; Esker, S (Salt Lake City, USA)
-
- P171 Prevalence and risk factors of vertebral fractures in patients on antiretroviral treatment**
Weiser-Smeke, A; Mata-Marín, J*; Liña-Amador, M; Espinoza-Armenta, B; Gil-Avila, A; Gaytán-Martínez, J (Mexico City, Mexico)
-
- P172 Quantifying fracture risk in clinical practice: treatment for osteoporosis should be considered in approximately one out of four HIV+ individuals ≥40 years**
Siakalis, G;* Protopapas, K; Makras, P; Katsarolis, I; Kavatha, D; Papadopoulos, A; Antoniadou, A (Athens, Greece)
-
- P173 Bone deficits in HIV mono-infected and HIV/HCV co-infected individuals belonging to the native Sicilian and migrant/refugee populations, demonstrated by DEXA scanning**
Lo Re, G; Di Carlo, P*; Gambino, A; Serra, N; Colomba, C; Lo Casto, A; Guglielmi, G; Cascio, A; La Galla, R (Palermo, Italy)
-
- P174 Cardiovascular events: a thing of the past? A real-life assessment in an inner-city Toronto clinic**
Crouzat, F;* Varriano, B; Sandler, I; Smith, G; Steinberg, S; Kovacs, C; Fletcher, D; Knox, D; Merkley, B; Chang, B; Tilley, D; Ascai, M; Sharma, M; Loutfy, M (Toronto, Canada)
-
- P175 Risk of cardiovascular disease events with atazanavir-based antiretroviral treatment regimens among HIV-infected veterans: a US national study**
LaFleur, J; Bress, A; Rosenblatt, L; Crook, J; Sax, P; Myers, J; Ritchings, C* (Salt Lake City, USA)
-
- P176 A reappraisal with meta-analysis of abacavir use and cardiovascular disease events**
Cruciani, M;* Parisi, S (Verona, Italy)

*Indicates presenting author.

POSTER PRESENTATIONS (continued)




- P177 Awareness and management of elevated blood pressure among HIV-infected adults receiving antiretroviral therapy in urban Zambia**
*Bauer, S**; Zyambo, Z; ma Mwanza, M; Chilengi, R; Davies, MA; Egger, M; Furrer, H; Vinikoor, M; Wandeler, G (Bern, Switzerland)
-
- P178 Reduction of immune activation in HIV-infected patients after introducing pitavastatin**
*Bernal Morell, E**; Martinez, M; Bravo, J; Vera, F; Martinez, O; Galera, C; Muñoz, A; Marín, I; Alcaraz, A; Cano, A; Valero, S; Gomez Verdu, J; Torres, A; Minguela, A (Murcia, Spain)
-
- P179 Extensive vascular phenotyping – for the detection of subclinical atheromatosis, arteriosclerosis and arterial hypertrophy – and its association with international cardiovascular prediction scores in HIV-infected individuals: a single-center study**
*Psichogiou, M**; Arida, K; Papadopoulou, M; Papaioannou, T; Lazarini, A; Konstantonis, G; Petrikos, P; Daikos, G; Kitas, G; Sfrikakis, P; Protogerou, A (Athens, Greece)
-
- P180 Initiation of antiretroviral therapy restores endothelial cell function in HIV-infected individuals**
*Echeverría, P**; Gómez-Mora, E; Roura, S; Bayés-Genis, A; Bonjoch, A; Puig, J; Pérez-Alvarez, N; Clotet Sala, B; Blanco, J; Negredo, E (Barcelona, Spain)
-
- P181 Cardiovascular risk factors and use of lipid-lowering therapy in a cohort of HIV-positive patients with high cardiovascular risk**
*Denman, J**; Manavi, K (Birmingham, UK)
-
- P182 Prevalence of cardiovascular diseases in West African HIV-infected adults receiving HAART**
*Ello, N**; Mossou, C; Coffie, P; Kouakou, A; Iklo, C; Anzoua-Kacou, J; Eholie, S (Abidjan, Ivory Coast)
-
- P183 Premature cerebral atherosclerosis in HIV-infected individuals in Lisbon: a carotid ultrasound and transcranial Doppler study**
*Pais de Lacerda, A**; Melo, M; Coelho, P; Baptista, P; Soares, F; Caldeira, L; Valadas, E; Oliveira, V (Lisbon, Portugal)
-
- P184 CVD risk assessment using various tools in an HIV cohort in Greece**
*Zouzia, E; Kakalou, E**; Papastamopoulos, V; Kakkavas, T; Dimas, D; Rosenberg, T; Skoutelis, A (Athens, Greece)
-
- P185 Myocardial inflammatory changes before and after ART in HIV-infected patients with advanced disease**
*Piñeirua Menendez, A**; Flores Miranda, R; Sánchez Nava, D; Ortega Pérez, R; Belaunzaran Zamudio, F; Pérez Patrigeon, S; Cardenas Ochoa, A; Oseguera Moguel, J; Galindo Uribe, J; Orihuela Sandoval, C; Vásquez Ortiz, Z; Vásquez Lamadrid, J; Morelos Guzmán, M; Rosales Uvera, S; Crabtree Ramírez, B; Sierra Madero, J (Mexico City, Mexico)
-
- P186 TDF/FTC/RPV + atorvastatin as co-morbidity-driven cART**
*Maggiolo, F**; Di Filippo, E; Comi, L; Callegaro, A; Valenti, D; Gregis, G (Bergamo, Italy)
-
- P187 Lipid profile in HIV patients with long-term ART: darunavir versus raltegravir versus rilpivirine**
*Branco Ascenção, B**; Casella, I; Gonçalves, C; Luís, N; Goes, A; Sá, J; Brito, A; Poças, J (Setubal, Portugal)
-
- P188 Cardiovascular disease risk scores comparison in Serbian HIV-infected patients**
*Dimitrijevic, B**; Jevtovic, D; Soldatovic, I; Ranin, J; Salemovic, D; Kusic, J; Dragovic, G (Belgrade, Serbia and Montenegro)
-

*Indicates presenting author.



- P189 The extent of B-cell activation and dysfunction preceding lymphoma development**
Shepherd, L; Borges, A; Harvey, R; Bower, M; Grulich, A; Silverberg, M; Weber, J; Ristola, M; Viard, J; Bogner, J; Gargalianos-Kakolyri, P; Mussini, C; Mansinho, K; Yust, I; Calmy, A; Paduta, D; Jilich, D; Smiatacz, T; Radoi, R; Tomazic, J; Plomgaard, P; Frikke-Schmidt, R; Lundgren, J; Mocroft, A; EuroSIDA in EuroCOORD (Copenhagen, Denmark)*
- P190 Survival in HIV-1-infected individuals with diagnosis of lymphoma compared to general population: data from the ICONA Foundation cohort**
Cingolani, A; Cozzi Lepri, A; Teofili, L; Galli, L; Mazzotta, V; Baldin, G; Hohaus, S; Bandera, A; Alba, L; Galizzi, N; Castagna, A; d'Arminio Monforte, A; Antinori, A; on behalf of the ICONA Foundation cohort (Rome, Italy)*
- P191 Cervical and breast cancer screening practices among women living with HIV**
Salters, K; Ye, M; Burchell, A; Pick, N; Smith, D; Jabbari, S; Hull, M; Shoveller, J; Montaner, J; Hogg, R (Burnaby, Canada)*
- P192 Immune suppression at cART initiation is associated with cancer development in women living with HIV/AIDS**
Salters, K; Ye, M; Pick, N; Smith, D; Wiseman, S; Jabbari, S; Hull, M; Shoveller, J; Montaner, J; Hogg, R (Burnaby, Canada)*
- P193 High rate of the progression of low squamous intraepithelial lesion (LSIL) to high squamous intraepithelial lesion (HSIL) in a cohort of HIV MSM in 'the modern antiretroviral era'**
Hidalgo-Tenorio, C; Gil Anguita, C; Ramirez Taboada, J; Lopez Ruz, M; Omar Momamed Balghata, M; Javier, R; Esquivias, J; Gutierrez, M; Pasquau, J (Granada, Spain)*
- P194 Relapse of HIV-associated multicentric Castleman's disease following rituximab-based immunotherapy**
Dalla Pria, A; Roe, J; Bracchi, M; Pagani, N; McFaul, K; Forni, J; Merchant, S; Samani, A; Byrne, R; Nelson, M; Bower, M (London, UK)*
- P195 Incidence of cancer in a cohort of HIV-positive patients on virologically suppressive antiretroviral therapy in Western India: a resource-limited setting perspective**
Dravid, A; Kulkarni, P; Saraf, C; Kulkarni, M; Kore, S; Rathod, N (Pune, India)*
- P196 Self-administered treatment with imiquimod 5% cream for intra-anal HSIL (AIN2/3) in HIV-positive patients: efficacy, safety and a comfortable option**
Hidalgo-Tenorio, C; Gil Anguita, C; Ramirez Taboada, J; De Jesus, S; Esquivias, J; Alvarez, M; Gutierrez, M; Lopez Ruz, M; Javier, R; Pasquau, J (Granada, Spain)*
- P197 Investigating barriers in HIV-testing oncology patients: the IBITOP study phase II**
Nguyen-Ngoc, T; Cavassini, M; Merz, L; Zimmermann, S; Peters, S; Darling, K (Lausanne, Switzerland)*
- P198 A descriptive study of cancer incidence in a cohort of HIV-infected patients followed since 1986**
Montejano, R; Arribas, J; Bernardino, J; Martin-Carbonero, L; Montes, M; Moreno, V; Perez-Valero, I; Gonzalez-Garcia, J; Valencia, E (Madrid, Spain)*
- P199 Human papilloma virus and HIV**
Popova, A; Kravtchenko, A; Deulina, M; Shipulina, O (Moscow, Russian Federation)*
- P200 Glucose metabolism disorders, HIV and antiretroviral therapy among Tanzanian adults**
Maganga, E; Smart, L; Kalluvya, S; Kataraih, J; Saleh, A; Obeid, L; Downs, J; Fitzgerald, D; Peck, R (Doha, Qatar)*

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P201** **Decreasing incidence of diabetes mellitus in HIV-positive Taiwanese patients on combination antiretroviral therapy from 2004 to 2013**
*Wu, P**; Yang, S; Lou, Y; Zhang, J; Chang, H; Sun, H; Sheng, W; Hsieh, S; Hung, C (Taipei, Taiwan)
-
- P202** **Comparison of risk tools to estimate type 2 diabetes risk in an urban HIV cohort**
*Mok, J**; Goff, L; Peters, B; Duncan, A (London, UK)
-
- P203** **Lipodystrophy as cause of metabolic syndrome: a contribution of antiretroviral drugs to increased cardiovascular risk**
*Muñoz-Mendoza, V**; Fontecha-Ortega, M; Gómez Ayerbe, C; Vivancos Gallego, M; Sánchez Conde, M; Casado Osorio, J (Teruel, Spain)
-
- P204** **Normalisation of undernutrition following initiation of HAART is not associated with future diabetes risk**
*Mok, J**; Goff, L; Peters, B; Duncan, A (London, UK)
-
- P205** **Hepatic steatosis is highly prevalent in HIV and significantly associated with diabetes risk**
*Mok, J**; Goff, L; Peters, B; Duncan, A (London, UK)
-
- P206** **HIV-positive inflammatory activity monitoring correlated to insulin resistance: HIRE study**
*Soares Medeiros, M**; Pires Moreira, H; Veras Da Ponte, D; dos Santos Araujo, A; Pereira de Brito Neves, A; Santos Souza, R; Lucena Chaves, H; Feitosa de Queiroga, M; Ximenes Paula, V; Antonio Gomes Arruda, E (Fortaleza, Brazil)
-
- P207** **A cross-sectional study of co-morbidities in HIV-infected patients receiving cART in Taiwan: a nationwide surveillance**
*Yang, C**; Wang, H; Chou, T; Chang, C (New Taipei City, Taiwan)
-
- P208** **Tryptophan metabolism and its relationship with central nervous system toxicity in subjects switching from efavirenz to dolutegravir**
 *Keegan, M**; Winston, A; Higgs, C; Fuchs, D; Boasso, A; Nelson, M (London, UK)
-
- P209** **Multicentre open-label pilot study of switching from efavirenz to dolutegravir for central nervous system (CNS) toxicity**
 *Bracchi, M; Pagani, N**; Clarke, A; Adams, T; Waters, L; Bolton, M; Winston, A; Mora-Peris, B; Dickinson, L; Boffito, M; Nelson, M (London, UK)
-
- P210** **Psychiatric adverse events from the DTG ART-naïve phase 3 clinical trials**
 *Quercia, R**; Roberts, J; Murungi, A; Curtis, L; Payvandy, N; Koteff, J; Aboud, M (Brentford, UK)
-
- P211** **Prevalence of undiagnosed neurocognitive impairment in HIV-infected adults taking efavirenz on a long-term basis with undetectable or low HIV RNA compared with protease inhibitors**
*Marques, N**; Fernandes, C; Tejo, S; Rosa, A; Nogueira, M; Rocha, S; Trêpa, J; Saraiva da Cunha, J (Almada, Portugal)
-
- P212** **Adverse events and discontinuation of dolutegravir-based therapy in naïve and experienced HIV patients: tertiary HIV centre experience**
*Fernandez, C**; Michie, K; Thomson-Glover, R; Chaponda, M; Ratcliffe, L (Liverpool, UK)
-
- P213** **Cerebrospinal fluid and plasma biomarkers in patients with HIV-associated neurocognitive disorders**
*Trunfio, M**; Vai, D; Romito, A; Atzori, C; Imperiale, D; Audagnotto, S; Montrucchio, C; Scabini, S; Cardellino, C; Pirriatore, V; Di Perri, G; Bonora, S; Calcagno, A (Turin, Italy)
-
- P214** **Incidence of CSF HIV escape in patients on virologically suppressive second-line protease inhibitor-based ART in Pune, Western India**
*Dravid, A**; Saraf, C; Kulkarni, M; Kore, S; Rathod, N; Mahajan, U (Pune, India)

*Indicates presenting author.

- P215 Monitoring of 8-hydroxy-efavirenz concentrations for management of mood changes**
Grilo, N; Correia, M; Sequeira, C; Harjivan, S; Caixas, U; Diogo, L; Marques, M; Monteiro, E; Antunes, A; Pereira, S (Lisbon, Portugal)*
-
- P216 The predictive role of cerebrospinal fluid (CSF)/plasma immune activation and neuronal injury biomarkers for HIV-associated neurocognitive disorders (HAND) diagnosis: a cross-sectional study**
Pinnetti, C; Fedele, V; Balestra, P; Carta, S; Lorenzini, P; Ammassari, A; Bordoni, V; Alba, L; Mazzotta, V; Grisetti, S; Martini, F; Ceccherini-Silberstein, F; Perno, C; Antinori, A (Rome, Italy)*
-
- P217 Neuro+3 study: cognitive evolution in HAND after 96 weeks of treatment intensification with higher CNS penetration score**
Force, G; De Truchis, P; Marigot-Outtandy, D; Le Du, D; Troisvallets, D; Blum, L; Ait-Mohand, H; Ghout, I; Hahn, V; Defferrière, H; Darchy, N; Lecornu, C; Brefort, S; Larroze, M; Sauvage, M; Delaugerre, C; Néré, M; Mahjoub, N; Peytavin, G (Levallois, France)*
-
- P218 Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir**

Jose, S; Nelson, M; Phillips, A; Chadwick, D; Trevelion, R; Jones, R; Williams, D; Hamzah, L; Sabin, C; Post, F (London, UK)*
-
- P219 Renal health after long-term exposure to tenofovir disoproxil fumarate (TDF) in HIV/HBV co-infected individuals in Sub-Saharan Africa: results from the HEPIK cohort**

Villa, G; Phillips, R; Smith, C; Stockdale, A; Beloukas, A; Appiah, L; Chadwick, D; Ruggiero, A; Sarfo, F; Post, F; Geretti, A (Liverpool, UK)*
-
- P220 Factors associated with decreased estimated glomerular filtration rate (eGFR) among HIV-1 positive persons in methadone program: data from Warsaw HIV Outpatient Clinic**
Mattoz, B; Pietraszkiewicz, E; Firlag-Burkacka, E; Grycner, E; Horban, A; Kowalska, J (Warsaw, Poland)*
-
- P221 Kidney tubular dysfunction and decline in renal function in HIV-infected Chinese people receiving tenofovir disoproxil fumarate**
Lui, C; Chan, P; Cheung, C; Lee, M; Naftalin, C; Chan, K; Wong, N; Lee, S (Hong Kong, Hong Kong)*
-
- P222 TDF, ATV/r and other ARV: renal safety in a resource-limiting country**
Beraldi de Magalhaes, F; Silva Penteado, S; Collodetto Soares, M; Claro Amaral, D; Mello Mazepa, M; Kato, P; Gomes da Silva, M (Curitiba, Brazil)*
-
- P223 Kidney transplant in HIV-positive population: outcomes and therapeutic perspectives in a 10-year experience**
Chirico, C; Izzo, I; Casari, S; Bossini, N; Brianese, N; Forleo, M; Focà, E; Sandrini, S; Castelli, F (Brescia, Italy)*
-
- P224 Renal function and chronic kidney disease prognosis through the lens of co-morbidities in people living with HIV infection: an association hard to escape**
Kalkounou, I; Retsas, T; Kourkounti, S; Katsarolis, I; Pappazos, V (Athens, Greece)*
-
- P225 Different classifications of chronic kidney disease (CKD) in HIV-infected patients result in large discrepancies in CKD prevalence in this population**
Gagneux-Brunon, A; Frésard, A; Guglielminotti, C; Cazorla, C; Lucht, F; Botelho-Nevers, E (Saint-Etienne, France)*
-
- P226 Urinary products of N-acetyltransferase 8 as indicators of kidney disease progression in HIV infection**
Dias, C; Diogo, L; Trigo, D; Campos, P; Lemos, A; Morello, J; Pacheco, P; Monteiro, E; Soto, K; Pereira, S (Lisbon, Portugal)*

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P227 Nephrotic range proteinuria in a patient with HIV infection and a history of intravenous drug abuse: case report and review of the literature**
*Tsilika, M**; Kavatha, D; Protopapas, K; Siakallis, G; Papadopoulos, A; Antoniadou, A (Athens, Greece)
-
- P228 Tolerability of integrase inhibitors in a real-life setting**
Padilla, M; Rojas, J; Gonzalez-Cordon, A; Blanco, J; Blanch, J; Lonca, M; Torres, B; Martinez-Rebollar, M; Laguno, M; Tricas, A; Rodriguez, A; Mallolas, J; Gatell, J; de Lazzari, E; Peñafiel, J; Martinez, E* (Barcelona, Spain)
-
- P229 Erythrocyte inosine triphosphatase activity: a potential biomarker for adverse events during combination antiretroviral treatment for HIV**
*Peltenburg, C**; Bierau, J; Bakker, J; Schippers, J; Lowe, S; Paulussen, A; van den Bosch, B; Leers, M; Hansen, B; Verbon, A (Rotterdam, The Netherlands)
-
- P230 Dolutegravir tolerability in clinical practice: results from the SCOLTA cohort**
*Madeddu, G**; Ricci, E; Gulminetti, R; Paola, B; Squillace, N; De Socio, G; Menzaghi, B; Giancarlo, O; Molteni, C; Rusconi, S; Celesia, B; Bellacosa, C; Di Biagio, A; Pellicanò, G; Martinelli, C; Carezzi, L; Valsecchi, L; Calza, L; Falasca, K; Vichi, F; Penco, G; Bonfanti, P (Sassari, Italy)
-
- P231 Prevalence, spectrum, predictors and screening of clinically significant chronic liver disease associated with didanosine use in HIV-infected individuals**
*Millard, J**; Gilleece, Y; Verma, S (London, UK)
-
- P232 Neurocognitive performance and psychological symptoms improve in HIV-positive patients switching from an efavirenz (EFV)- to a rilpivirine (RPV)-based cART**
*Pinnetti, C**; Ricottini, M; Balestra, P; Lorenzini, P; Libertone, R; Mazzotta, V; Plazzi, M; Bellagamba, R; Zaccarelli, M; Antinori, A; Ammassari, A (Rome, Italy)
-
- P233 First-line ARV treatment characteristics among HIV-infected patients with and without co-morbidities**
*Prajapati, G**; Zhang, D; Goodwin, B (Rahway, USA)
-
- P234 Adverse events occurring after introduction of EVG/COBI/FTC/TDF: data from the Surveillance COhort Long-term Toxicity Antiretrovirals/antivirals (SCOLTA) cohort**
*Squillace, N**; Bonfanti, P; Ricci, E; Calza, L; Celesia, B; Martinelli, C; Vichi, F; Cordier, L; Carezzi, L; Franzetti, M; De Socio, G; Peruzzu, F; Orofino, G; Bellacosa, C; Di Biagio, A; Gori, A; Quirino, T (Monza, Italy)
-
- P235 Prevalence of smoking and nicotine dependence in HIV patients, the project STOPS HIV from Italy**
*De Socio, G**; Ricci, E; Dell'Omo, M; Maggi, P; Schiaroli, E; Santoro, C; Squillace, N; Angeli, G; Patacca, A; Tiri, B; Abeli, C; Madeddu, G; Magnè, F; Molteni, C; Vichi, F; Francisci, D; Baldelli, F (Perugia, Italy)
-
- P236 Soft modelling of health-related quality of life specific to HIV in relation to anxiety, depression, personality traits and precariousness**
*Duracinsky, M**; Lalanne, C; Piroth, L; Aboromman, M; Weiss, L; Rami, A; Chassany, O (Paris, France)
-
- P237 Prevalence and predictors of HPV infection at oral cavity and anal site: findings in an Italian anal cancer screening program for HIV-positive males**
Garbuglia, A; Piselli, P; Gentile, M; Del Nonno, F; Sias, C; Lapa, D; Libertone, R; Lupi, F; Baiocchini, A; Capobianchi, M; Ammassari, A* (Rome, Italy)
-
- P238 Prevalence and presentation of syphilitic hepatitis in HIV-infected patients**
*Raycraft, T**; Alimohammadi, A; Singh, A; Kiani, G; Shahi, R; Hakobyan, S; Conway, B (Vancouver, Canada)
-

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P239 The impact of engagement in care on the life expectancy of people living with HIV**
*Jose, S**; May, M; Sabin, C (London, UK)
-
- P240 Long sleep and longer naps are associated with severity of HIV disease**
*Faraut, B; Malmartel, A; Ghosn, J; Duracinsky, M**; Léger, D; Grabar, S; Viard, J (Paris, France)
-
- P241 High rates of alcohol and illicit drug consumption among HIV-infected patients attended in Spain**
*Gonzalez-Baeza, A**; Hontañon-Antoñana, V; Caceres, G; Montes, J; Perez-Valero, I (Madrid, Spain)
-
- P242 Common co-morbidities found in a population of clinically stable HIV-infected patients on chronic antiretroviral therapy in five ambulatory clinics in Lima-Callao, Peru**
*Hidalgo, J**; Florez, A; Agurto, C; Pinedo, Y; Gutierrez, R; Rodriguez, L; Ayarza, R (Lima, Peru)
-
- P243 Quality of life in an Italian cohort of women living with HIV: preliminary results from IANUA study (Investigation on Antiretroviral Therapy)**
*Venturini, A; Cenderello, G; Giannini, B; Montefiori, M; Di Biagio, A; Penco, G**; Mazzarello, G; Orcamo, P; Merlano, C; Setti, M; Giacomini, M; Viscoli, C; Cassola, G (Genoa, Italy)
-
- P244 Seasonal variations in vitamin D levels in HIV-infected patients: when to test for hypovitaminosis?**
*Noe, S; Heldwein, S; Pascucci, R; Oldenbuettel, C; von Krosigk, A; Wiese, C; Jaegel-Guedes, E; Jäger, H; Mayer, W; Wolf, E; Spinner, C** (Munich, Germany)
-
- P245 Utilizing US prescription and claims data to better understand treatment dynamics of HIV/HCV co-infection patients in the second generation DAA era**
*Denarie, M; Gubernick, S**; Panchatcharam, N; Gao, S; O'Neil, S; Arluck, J (Plymouth Meeting, USA)
-
- P246 Comparison of early serologic response of early syphilis to treatment with a single-dose benzathine penicillin G between HIV-positive and HIV-negative patients: a cohort study**
*Su, Y; Chang, L; Liu, W; Wu, C; Yang, C**; Hung, C (New Taipei City, Taiwan)
-
- P247 Cognitive and emotional functioning in HIV-infected MSM treated with effective antiretroviral therapy**
*Szymańska, B**; Łojek, E; Gawron, N; Cholewińska, G; Firlag-Burkacka, E; Horban, A; Borstein, R (Warsaw, Poland)

Viral Hepatitis

- P248 TURQUOISE-I part 2: safety and efficacy of ombitasvir + paritaprevir/r ± dasabuvir with or without RBV in patients with HIV-1 and HCV GT1 or GT4 co-infection**
*Rockstroh, J; Orkin, C**; Viani, R; Wyles, D; Luetkemeyer, A; Lazzarin, A; Soto-Malave, R; Nelson, M; Bhagani, S; Klinker, H; Rizzardini, G; Girard, P; Shulman, N; Hu, Y; Fredrick, L; Trinh, R; Gane, E (London, UK)
-
- P249 New findings in HCV genotype distribution in selected West European, Russian and Israeli regions**
*Kartashev, V; Doering, M; Nieto, L; Coletta, E; Heger, E; Neumann-Fraune, M; Kaiser, R; Sierra, S** (Cologne, Germany)
-
- P250 Progression of liver fibrosis among HIV-infected patients under suppressive antiretroviral therapy: role of untreated HCV and other unrelated factors in the ICONA Foundation study cohort**
*Lapadula, G**; Soria, A; Lorenzini, P; De Luca, A; Puoti, M; Antinori, A; Mastroianni, C; Cassola, G; Bonora, S; Santoro, M; Gori, A; d'Arminio Monforte, A (Monza, Italy)

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P251 Hepatitis C can be cured for less than \$100 per person: analysis of drug exports from India**
Hill, A^{*}; Gotham, D; Barber, M; Pozniak, A; Fortunak, J (London, UK)*
-
- P252 Hepatitis C virus screening project of patients on current anti-HCV therapy**
Knops, E; Kalaghatgi, P; Neumann-Fraune, M; Heger, E; Schülter, E; Timm, J; Walker, A; Lengauer, T; Keitel, V; Goeser, T; Esser, S; von Hahn, T; Pauser, I; Qurishi, N; Roemer, K; Scholten, S; Daeumer, M; Obermeier, M; Kaiser, R; Sierra, S (Cologne, Germany)*
-
- P253 Are HIV/HCV co-infected patients more likely to experience multiple lines of ART than HIV mono-infected patients? Results from the ICONA Foundation study**
Marchetti, G^{*}; Bruno, R; Shanyinde, M; Mussini, C; Caramello, P; Zaccarelli, M; Andreoni, M; d'Arminio Monforte, A; Cozzi-Lepri, A (Milan, Italy)*
-
- P254 Rapid decline of anti-HCV antibodies following treatment of incident HCV infection in HIV-infected MSM in the Swiss HIV Cohort Study (SHCS)**
Aebi-Popp, K^{*}; Wandeler, G; Salazar-Vizcaya, L; Fehr, J; Stoeckle, M; Hoffmann, M; Suter-Riniker, F; Luethi, A; Calmy, A; Cavassini, M; Bernasconi, E; Rauch, A (Bern, Switzerland)*
-
- P255 Effectiveness of hepatitis A vaccination in HIV-positive men who have sex with men during an ongoing hepatitis A outbreak in Taiwan**
Lin, K^{*}; Wu, P; Liu, W; Sun, H; Lo, Y; Hsieh, S; Sheng, W; Chuang, Y; Chen, G; Hung, C; Chang, S (Taipei, Taiwan)*
-
- P256 High sustained virological response rates using imported generic direct-acting antiviral treatment for hepatitis C, imported into Australia, UK, Europe and North America**
Hill, A^{*}; Savage, A; Jeffreys, G; Sallie, R; Kennedy, A; Ngoc Nieu, P; Freeman, J; Freeman, J (London, UK)*
-
- P257 Long-term virologic and serologic response of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in HIV-positive patients**
Huang, Y; Su, Y; Liu, W; Chang, S; Sheng, W; Sun, H; Hsieh, S; Chuang, Y; Hung, C^{*}; Chang, S (Hsin-Chu, Taiwan)*
-
- P258 The emergence of hepatitis C virus genotype 4d infection in men who have sex with men**
Sutcliffe, L^{*}; Thomson, E (Glasgow, UK)*
-
- P259 SOF/VEL single-tablet regimen in HCV mono-infected and HIV/HCV co-infected patients: comparison of efficacy and safety data from phase 3 clinical trials**
Wyles, D; Brau, N; Naggie, S; Sulkowski, M; Agarwal, K; Patel, K; Afdhal, N; Liu, L; Ding, X; Huang, K; Osinusi, A; McNally, J; Brainard, D; Mertens, M^{*}; McHutchison, J (London, UK)*
-
- P260 HIV/hepatitis C co-infected patients are significantly more complex to manage than HIV mono-infected patients in a large cohort of treatment-naïve, HIV-positive individuals**
Dieterich, D^{*}; Fusco, J; Henegar, C; D'Amico, R; Schulman, K; Zelt, S; Lackey, P (New York, USA)*
-
- P261 Efficacy of generic direct-acting antiviral treatment for hepatitis C, imported into Russia and Eastern Europe**
Hill, A^{*}; Dragunova, J; Korologou-Linden, R; Golovin, S (London, UK)*
-
- P262 High sustained virologic response rates using generic direct-acting antiviral treatment for hepatitis C, imported into Southeast Asia**
Korologou-Linden, R^{*}; Hill, A; Wardhana, A; Khwairakpam, G (London, UK)*
-

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P263** **Is ART use associated with an increased risk of ALT elevation in HIV/HCV co-infected patients over and above what is expected in HIV mono-infected patients? A nested case-control analysis**
*Shanyinde, M**; Marchetti, G; Bruno, R; Ceccherini-Silberstein, F; Gori, A; De Luca, A; Vecchiet, J; Lichtner, M; Madeddu, G; Bonfanti, P; d'Arminio Monforte, A; Cozzi-Lepri, A; on behalf of the ICONA Foundation cohort (London, UK)
-
- P264** **Long-term trends in HCV treatment uptake, efficacy and liver disease in the SHCS**
*Béguelin, C**; Sutter, A; Bernasconi, E; Braun, D; Kovari, H; Bucher, H; Stoeckle, M; Cavassini, M; Rougemont, M; Schmid, P; Rauch, A (Bern, Switzerland)
-
- P265** **Effectiveness of all-oral DAAs for HCV genotype 4 in HIV/HCV co-infected subjects with compensated liver disease: real-world experience from the MADRID-CoRe study**
*Gonzalez-Garcia, J**; Aldamiz-Echevarria, T; Quereda, C; Hontañon, V; Dominguez-Dominguez, L; Gil-Martin, A; Cruz-Martos, E; Tellez, M; Santos, I; Cuevas-Tascon, G; Gaspar, G; Alvarez-Alvarez, B; Losa, J; Cervero, M; Barros, C; Mosalvo, R; Menendez, M; Belda, L; Calvo, M; Alcaraz, M; Jarrin, I; Berenguer, J (Madrid, Spain)
-
- P266** **Continued increase of recent hepatitis C virus infections among HIV-positive patients in Taiwan**
*Liu, W; Su, L; Wu, C; Wu, P; Yang, S; Zhang, J; Chang, H; Chang, S; Liu, C; Sun, H; Hung, C**; Chang, S (Taipei, Taiwan)
-
- P267** **Treatment failure with DAAs in chronic hepatitis C: a Portuguese multicenter report**
*Valente, C**; Casella, M; Faria, D; Aleixo, M; Vaz Pinto, I; Mota, M; Mingo, A; Carvalho, A; Roxo, F; Faísca, R; Proença, P; Poças, J; Prata, M; Marques, N; Saraiva Cunha, J (Coimbra, Portugal)
-
- P268** **Seroepidemiology of hepatitis A virus among HIV-positive patients in Taiwan in the setting of acute hepatitis A outbreak in 2015–2016**
*Chen, G**; Lin, K; Sun, H; Sheng, W; Hsieh, S; Chuang, Y; Hung, C; Chang, S (Taipei, Taiwan)
-
- P269** **Different impact of DAA on innate and adaptive cellular immunity in HIV/HCV co-infected and HCV mono-infected patients**
*Zuccalà, P**; Lichtner, M; Vita, S; Marocco, R; Mascia, C; Savinelli, S; Campagna, M; Mengoni, F; Tieghi, T; Pozzetto, I; D'Ettorre, G; Paoletti, F; Mastroianni, C; Vullo, V (Rome, Italy)
-
- P270** **Real-life renal impact of ledipasvir/sofosbuvir on a cohort of HIV-infected patients treated with tenofovir combined with a boosted protease inhibitor**
*Cabo, J**; Garrote, A; Simões, P; Póvoas, D; Gonçalves, R; Ramirez, F; Betkova, S; Seixas, D; Alves, L; Manata, M; Garrido, N; Cardoso, O; Cardoso, S; Lino, S; Martins, T; Maltez, F (Lisbon, Portugal)
-
- P271** **Changes in lipid profile during and after hepatitis C virus (HCV) treatment with direct-acting antiviral (DAA), interferon-free regimens in patients co-infected with HIV**
*Domínguez-Domínguez, L**; Bisbal, O; Lagarde, M; Matarranz, M; Hernando, A; Rubio, R; Pulido, F (Madrid, Spain)
-
- P272** **HIV/hepatitis C co-infection: successfully treating hepatitis C with direct-acting antivirals and managing those who do not access traditional care**
*Metcalfe, R**; Bulteel, N; Schofield, J; McGinness, P; Glover, C; McLean, L; Marra, F; Murphy, A; Peters, E; Bell, D; Fox, R; Thomson, E (Glasgow, UK)
-
- P273** **Improving of glycemic control associated with DAAs HCV treatment persists at SVR12**
*Pavone, P**; d'Ettorre, G; Lichtner, M; Tieghi, T; Marocco, R; Mezzaroma, I; Passavanti, G; Mastroianni, C; Vullo, V (Rome, Italy)

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P274** **Ledipasvir/sofosbuvir for 12 or 24 weeks in HCV genotype 1 in HIV/HCV co-infected subjects with compensated liver disease: real-world experience from the MADRID-CoRe study**
*Berenguer, J**; Moreno, A; Martín-Carbonero, L; Domínguez, L; Aldámiz-Echevarría, T; Gil-Martín, Á; Cruz-Martos, E; Vergas, J; Santos, I; Benítez, L; De Miguel, J; Troya, J; Álvarez, B; Torres, R; Canalejo, E; Arponen, S; de Guzmán, M; Gotuzzo, L; Calvo, M; Alcaraz, M; Jarrin, I; González-García, J (Madrid, Spain)
-
- P275** **Seroepidemiology of hepatitis B virus (HBV) infection among HIV-positive men who have sex with men born in the era of nationwide neonatal HBV vaccination in Taiwan**
*Huang, Y**; Yang, S; Liu, W; Wu, P; Sun, H; Sheng, W; Hsieh, S; Hung, C; Chang, S (Taipei City, Taiwan)
-
- P276** **Liver fibrosis regression in HIV-HCV co-infected individuals after sustained virologic response with HCV direct-acting antivirals**
*Arias, A**; Lledó, G; Treviño, A; Benítez-Gutierrez, L; Carrasco, I; Cuervas-Mons, V; De Mendoza, C (Madrid, Spain)
-
- P277** **Treatment rate for HCV in the DAAs era in HIV co-infected patients: data from an Italian cohort**
*Cuomo, G**; Puzzolante, C; Mussini, C; Borghi, V (Modena, Italy)
-
- P278** **The elderly and direct antiviral agents (DAAs): constraint or challenge?**
*Fabrizio, C**; Bruno, G; Milano, E; Dell'Acqua, R; Monno, L; Lo Caputo, S; Milella, M; Saracino, A; Angarano, G (Bari, Italy)
-
- P279** **Treating HCV-positive Italian inmates with direct-acting antivirals: the clinical experience in three major correctional houses of Milan**
*Ranieri, R**; Foschi, A; Casana, M; Radice, A; D'Angelo, C; De Bona, A; Bai, F; Lari, C; d'Arminio Monforte, A (Milan, Italy)
-
- P280** **Effectiveness of dasabuvir, ombitasvir/paritaprevir/ritonavir (DSV+OBV/PTV/r) for HCV genotype 1 in HIV/HCV co-infected subjects with compensated liver disease: real-world experience from the MADRID-CoRe study**
*Gonzalez-Garcia, J**; Montes-Ramírez, M; Dominguez-Dominguez, L; Aldamiz-Echevarria, T; Vivancos, M; Gil-Martin, A; Cruz-Martos, E; Estrada, V; Arias, A; Sanz, J; Gaspar, G; Losa, J; Barros, C; Ruiz-Giardin, J; Gimeno-Garcia, A; Vegas, A; Garcia-Benayas, M; Serrano, R; Calvo, M; Alcaraz, M; Jarrin, I; Berenguer, J (Madrid, Spain)
-
- P281** **Response to DAA-based regimens in genotype 4 chronic HCV/HIV co-infected patients in real life: COINFECOVA-2-SEICV study**
*Minguez, C**; García-Deltoro, M; Flores, J; Montero, M; Carmena, J; Galindo, M; Reus, S; Ballester, J; Usó, J; Ortega, E; SEICV Study Group, for the COINFECOVA-2 SEICV Study Group (Castellón, Spain)
-
- P282** **The role of two non-invasive tests to evaluate the liver fibrosis (FIB-4 and transient elastography) and its implications in the different HCV genotypes in a cohort of HIV/HCV co-infected patients**
*Perez Martinez, L**; Lapresta, C; Gracia, M; Moreno, J; Cecilio, A; Rubio, T; Irigoyen, C; Samperiz, G; Sanjoaquin, I; Blanco, J (Logroño [La Rioja], Spain)
-
- P283** **Diversity of hepatitis C virus envelope associated with fibrosis in treatment-naïve patients**
*Banica, L**; Paraschiv, S; Neaga, E; Gheorghita, V; Batan, I; Vlaicu, O; Popescu, C; Otelea, D (Bucharest, Romania)
-

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P284 Ledipasvir/sofosbuvir for 8 or 12 weeks in GT1 HCV-infected, treatment-naïve, non-cirrhotic patients with HIV infection: real-world experience from the MADRID-CoRe study**
*Berenguer, J**; Gil-Martin, A; Moreno, A; Moreno, F; Dominguez, L; Aldámiz-Echevarría, T; Cruz-Martos, E; Estrada, V; Santos, I; Benítez, L; Sanz, J; Ryan, P; Gaspar, G; Álvarez, B; Losa, J; Jurdado, J; Barros, C; Malmierca, E; Calvo, M; Alcaraz, M; Jarrin, I; González-García, J (Madrid, Spain)
-
- P285 Effect of mono/dual antiretroviral therapy on HCV and HIV suppression during HCV treatment in HIV/HCV co-infected patients**
*Martín-Carbonero, L**; Dominguez, L; Bailón, L; Torres, R; Rubio, R; Ron, R; Rico, M; Jiménez-Nacher, I; Moreno, F; González, J; Pulido, F; Montes, M (Madrid, Spain)
-
- P286 Health resources use in patients with HIV: evidence from Italian administrative databases**
*Perrone, V**; Sangiorgi, D; Crovato, E; Buda, S; Degli Esposti, L (Ravenna, Italy)
-
- P287 HCV+ and HIV/HCV+ patients treated with direct antiviral agents (DAAs): to what extent do they differ?**
*Bruno, G**; Fabrizio, C; Dell'Acqua, R; Milano, E; Milella, M; Saracino, A; Monno, L; Angarano, G (Bari, Italy)
-
- P288 Renal safety of boosted PI in HIV/HCV patients on SOF/LDV**
*Vivancos-Gallego, M**; Moreno, A; Perez Elías, M; Quereda, C; Casado, J; Sanchez-Conde, M; Navas, E; Del Campo, S; Moreno, S (Madrid, Spain)
-
- P289 Entecavir plus lamivudine as an alternative treatment for co-infected HBV/HIV patients with toxicity on tenofovir therapy**
*Fontecha-Ortega, M**; Muñoz-Mendoza, V; Monsalvo, M; Mateos, M; Rodríguez-Sagrado, M; Gómez, C; Casado, J (Madrid, Spain)
-
- P290 Direct-acting antiviral drugs (DAAs) for the treatment of chronic HCV infection in HIV co-infected patients: a monocentric experience in real life**
*Izzo, I**; Casari, S; Vavassori, A; Nasta, P; Odolini, S; Castelnuovo, F; Bergamasco, A; El Hamad, I; Paraninfo, G; Spinetti, A; Zaltron, S; Urbinati, L; Biasi, L; Focà, E; Festa, E; Cristini, G; Castelli, F (Brescia, Italy)
-
- P291 Daclatasvir (DCV) pharmacokinetics in HCV/HIV co-infected patients co-administered with rilpivirine and other antiretroviral drugs**
*Barco, A**; Marinaro, L; Merli, M; Alcantarini, C; Montrucchio, C; Vendemiati, G; Milesi, M; Patti, F; Favata, F; Ariaudo, A; Hasson, H; D'Avolio, A; Uberti-Foppa, C; Di Perri, G; Bonora, S (Turin, Italy)
-
- P292 Chronic HCV genotype 4 infection in a Portuguese cohort of co-infected HIV patients: treatment with sofosbuvir-based regimens**
*Brogueira, P**; Moneti, V; Miranda, A; Ventura, F; Baptista, T; Borges, F; Nina, J; Peres, S; Aldir, I; Campos, M; Antunes, I; Pereira, J; Mansinho, K (Lisbon, Portugal)
-
- P293 Mortality during direct-acting antiviral therapy in HCV/HIV patients with cirrhosis**
*Vivancos-Gallego, M**; Moreno, A; Perez Elías, M; Quereda, C; Casado, J; Gomez Ayerbe, C; Sanchez-Conde, M; Del Campo, S; Moreno, S (Madrid, Spain)
-
- P294 Characteristics and effectiveness in HCV mono-infected and HIV-HCV co-infected cirrhotic patients receiving oral direct-acting antiviral (DAA) regimens interferon-free therapies in southern Spain**
*Alcaraz, B; Vera, F; Escribano, P**; Rojano, R; Jimeno, A; Ruiz, E; Garcia, A; Trujillo, J; Cobos, N; Bernal, E; Alcalde, M; Garcia, J; Martinez, O; Capozzi, M; Martinez, L (Cartagena, Spain)

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P295** **Chronic hepatitis C treatment with direct antiviral drugs in mono- and HIV co-infected patients: a real-life experience in an infectious diseases department at a hospital in Portugal**
*Cabo, J**; Martins, T; Garrido, N; Betkova, S; Manata, M; Alves, L; Cardoso, S; Cardoso, O; Gonçalves, R; Garrote, A; Simões, P; Ramirez, F; Seixas, D; Lino, S; Maltez, F; Póvoas, D (Lisbon, Portugal)
-
- P296** **Chronic HCV treatment with DAA: what changes when treating cirrhotic patients – a Portuguese cohort real-life experience**
*Miranda, A**; Azevedo, T; Cruz, I; Ventura, F; Baptista, T; Borges, F; Peres, S; Aldir, I; Nina, J; Antunes, I; Campos, M; Pereira, J; Mansinho, K (Lisbon, Portugal)
-
- P297** **Chronic hepatitis C in HIV-infected patients: treatment in real life with new generation direct-acting antivirals in a Portuguese centre**
*Silva-Pinto, A; Ruas, R; Abreu, I; Ceia, F; Figueiredo, C; Carvalho, A; Santos, A; Soares, J; Piñeiro, C; Serrão, R**; Sarmiento, A (Porto, Portugal)
-
- P298** **Impact of HCV RNA kinetics in SVR12 in a cohort of HIV/HCV co-infected patients treated with DAAs in a 'real-life' setting**
*Cavinato, S; Zuin, S; Marini, G; Barbaro, F; Parisi, S; Cattelan, A** (Padua, Italy)
-
- P299** **CD4 cell count before chronic hepatitis C (HCV) treatment with direct-acting antivirals (DAAs) and at the end of follow-up in HCV/HIV co-infected patients**
*Mendez, J; Soeiro, C**; Marques, M; Gonçalves, C; Tavares, A; Horta, A; Vasconcelos, O; Seabra, J; Abreu, M; Sarmiento e Castro, R (Porto, Portugal)
-
- P300** **Testing for HCV and HIV at baseline visit due to post-exposure prophylaxis**
*Kowalska, J**; Pietraszkiwicz, E; Firlag-Burkacka, E; Pyziak-Kowalska, K; Horban, A (Warsaw, Poland)
-

Clinical Pharmacology

- P301** **Interactions between HIV and HCV therapies: how common and who wins?**
*Torkington, A**; Barnes, J; Cripps, S; Lee, K; Marshall, N; Morgan, H; Pratt, A; Sayers, I; Swabe, J; Swaden, L; Selby, P; Vaghjiani, T; Zimmer, M; Bhagani, S; Collier, J; Macdonald, D; Nelson, M; Prince, M; Wright, M; Ustianowski, A (Manchester, UK)
-
- P302** **Efavirenz significantly decreases etonogestrel exposure: results of a bidirectional pharmacokinetic evaluation of efavirenz- and nevirapine-based antiretroviral therapy plus etonogestrel contraceptive implants**
*Chappell, C**; Scarsi, K; Nakalema, S; Chen, B; Riddler, S; Cohn, S; Darin, K; Achilles, S; Lamorde, M (Pittsburgh, USA)
-
- P303** **Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?**
*Cattaneo, D**; Minisci, D; Cozzi, V; Riva, A; Meraviglia, P; Clementi, E; Rizzardini, G; Gervasoni, C (Milan, Italy)
-
- P304** **Determinants of dolutegravir plasma concentrations in the clinical setting**
*Alcantarini, C; Calcagno, A**; Marinaro, L; Ferrara, M; Milesi, M; Trentalange, A; Barco, A; Montrucchio, C; De Nicolò, A; Ariauo, A; Favata, F; D'Avolio, A; Di Perri, G; Bonora, S (Turin, Italy)
-
- P305** **Pharmacokinetics (PK) of darunavir/ritonavir (DRV/RTV) with tenofovir DF/emtricitabine (TDF/FTC) or raltegravir (RAL) in HIV-infected adults enrolled in the NEAT001/ANRS143 study and relationship with virological response**
*Bonora, S; Stohr, W; D'Avolio, A; Cursley, A; Molina, J; Faetkenheuer, G; Vandekerckhove, L; Di Perri, G; Pozniak, A; Richert, L; Raffi, F; Boffito, M** (London, UK)
-

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P306 Evaluation of the drug-drug interaction (DDI) potential between elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide and atorvastatin**
Custodio, J; West, S; SenGupta, D; Zari, A; Humeniuk, R; Ling, K; Fordyce, M; Kearney, B (Foster City, USA)*
-
- P307 Steady-state pharmacokinetics (PK) of atazanavir/cobicistat and darunavir/cobicistat once daily over 72 hours in healthy volunteers: the importance of PK forgiveness in clinical practice**
Elliot, E; Amara, A; Pagani, N; Else, L; Moyle, G; Schoolmeesters, A; Higgs, C; Khoo, S; Boffito, M (London, UK)*
-
- P308 Association of SLCO1B1 521T>C (rs4149056) with darunavir/ritonavir (DRV/r) plasma concentrations in HIV-infected individuals enrolled in the NEAT001/ANRS143 study**
Gurjar, R; Boffito, M; D'Avolio, A; Schwimmer, C; Yazdanpanah, Y; Doroana, M; Di Perri, G; Bonora, S; Pozniak, A; Richert, L; Raffi, F; Owen, A (Liverpool, UK)*
-
- P309 When food can make the difference: the case of elvitegravir-based coformulation**
Gervasoni, C; Baldelli, S; Minisci, D; Meraviglia, P; Clementi, E; Galli, M; Cattaneo, D (Milan, Italy)*
-
- P310 Impact of food on the bioavailability of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (DCFTAF), the first protease inhibitor-based complete HIV-1 regimen**
Crauwels, H; Baugh, B; Van Landuyt, E; Vanveggel, S; Hijzen, A; Opsomer, M (Raritan, USA)*
-
- P311 Prevalence of drug-drug interactions (DDI) and its impact on durability among patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/C/F/T) and concomitant medication**
Gomez-Ayerbe, C; Del Campo, S; Vivancos, M; Gaspar, G; Moreno, A; Martin, A; Romero, A; Jimenez, P; Cervero, M; Rodriguez-Sagrado, M; Serrano, R; Muriel, A; Pérez Elias, M (Madrid, Spain)*
-
- P312 Relationships between dolutegravir plasma-trough concentrations, UGT1A1 genetic polymorphisms and side-effects of the central nervous system in Japanese HIV-1-infected patients**
Yagura, H; Watanabe, D; Ashida, M; Nakauchi, T; Tomishima, K; Togami, H; Hirano, A; Sako, R; Doi, T; Yoshino, M; Takahashi, M; Yamazaki, K; Uehira, T; Shirasaka, T (Osaka, Japan)*
-
- P313 S-protein thiol-omics to assess the redox-modulation effects of antiretroviral drugs**
Correia, M; Dias, C; Caixas, U; Grilo, N; Lemos, A; Trigo, D; Pacheco, P; Monteiro, E; Soto, K; Diogo, L; Pereira, S (Lisbon, Portugal)*
-
- P314 Utilizing phase 3 clinical trial data to assess adverse event (AE) frequency of a potentially interacting medication (PIM) amlodipine with elvitegravir/cobicistat (EVG/COBI)**
Podzamczar, D; Tashima, K; Daar, E; McGowan, J; Campbell, T; Slim, J; Thompson, M; Guo, S; Borg, P; Haubrich, R; Das, M; McNicholl, I; McCallister, S (Foster City, USA)*
-
- P315 Real-world antiretroviral plasma levels in HIV-positive patients treated with sofosbuvir-containing DAA for hepatitis C infection**
Tempestilli, M; Fabbri, G; Timelli, L; Zaccarelli, M; Bellagamba, R; Cicalini, S; Lupi, F; Gallo, A; Libertone, R; Fazio, S; Antinori, A; Ammassari, A (Rome, Italy)*
-
- P316 Detection and analysis of antiretroviral medication errors by a clinical pharmacist in hospitalized HIV patients**
Pablos Bravo, S; García Muñoz, C; Pulido, F; Lázaro Cebas, A; Ferrari Piquero, J (Madrid, Spain)*
-
- P317 Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single-centre cohort of HIV-positive patients**
Salvaggio, S; Giacomelli, A; Falvella, F; Oreni, L; Meraviglia, P; Atzori, C; Clementi, E; Galli, M; Rusconi, S (Milan, Italy)*

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

P318 Prevalence of drug-drug interactions involving antiretroviral treatment: impact of the integrase inhibitor class

Messiaen, P; Baecke, C; van der Hilst, J (Hasselt, Belgium)*

P319 Temporal trend of the plasma level of efavirenz: comparison between CYP2B6-516 GG and GT genotype

Wong, C; Chan, P; Lee, S (Hong Kong, Hong Kong)*

Community Initiatives

P320 European survey on doctor-patient relationship

Kelly, D; Jachnowitsch, K; Raskevich, Y; Petkovic, N; West, B; Uyanik, D; Hodgson, I; Darakjian, V; Garrido Fuentes, J; Morton, J; Mukelabai, N; Bleak, S; Dessler, S; Mladenovic, N; Antoniadi, C (Brussels, Belgium)*

P321 HIV testing in the community: responding to the Glasgow outbreak

Middleton, L (Glasgow, UK)*

P322 Factors influencing and associated with the decision to join in Thailand's first online supervised HIV self-testing and counseling initiative

Anand, T; Nitpolprasert, C; Kerr, S; Apornpong, T; Ananworanich, J; Phanuphak, P; Phanuphak, N (Bangkok, Thailand)*

P323 Ways in which legal and regulatory barriers hinder the HIV care continuum and 90/90/90 target across Europe

Power, L; Hows, J; Raben, D; Finne Jakobsen, S; Croxford, S (Cardiff, UK)*

P324 Integrated HIV, hepatitis B and hepatitis C testing during the 2015 European testing week

Sperle, I; West, B; Delpech, V; Noori, T; Zakowicz, A; Von Lingen, A; Dedes, N; Farrel, J; Daamen, C; Begovac, J; Power, L; James, C; Collins, B; Kovacs, T; Fernandes, R; Dominković, Z; Raben, D (Copenhagen, Denmark)*

Models of Care

P327 Modelling the cost-effectiveness of HIV care in Poland shows clear benefits, while transmission risk is considered in the calculations

Kowalska, J; Wójcik, G; Rutkowski, J; Ankiersztejn-Bartczak, M; Siewaszewicz, E (Warsaw, Poland)*

P328 Targeting HIV testing at a population level: cost-effectiveness of three approaches

Gomez Ayerbe, C; Muriel, A; Reverte, C; Perez Elias, P; Del Campo, S; Vivancos, M; Santos, C; Calonge, M; Uranga, A; Moreno, A; Moreno, S; Casado, J; Perez Elías, M (Madrid, Spain)*

P329 HIV linkage to care: impact of a proactive intervention in a health area of Spain

del Campo, S; Gómez Ayerbe, C; Vivancos Gallego, M; Moreno Zamora, A; Casado Osorio, J; Loza de Bobadilla, E; Galán Montemayor, J; Rodríguez Domínguez, M; Drona Nuñez, F; Sanchez Conde, M; Moreno Guillén, S; Pérez Elías, M (Madrid, Spain)*

P331 Retention of mother-baby pairs in care and treatment through mother-baby care point initiative in Eastern Uganda

Abwola Olwedo, M; Lukoda, N; Crandall, B (Mbale, Uganda)*

P332 Efficiency of antiretroviral therapy in Russia

Pokrovskaya, A; Kozyrina, N; Guschina, U; Suvorova, Z; Yurin, O; Pokrovskiy, V (Moscow, Russian Federation)*

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P333 Closing the gap of perinatal HIV infection in Hong Kong**
Wong, C; Lin, W; Wong, K (Hong Kong, Hong Kong)*
-
- P334 'The first 90': how close can we get with home-based HIV testing? First results from recruitment for the CASCADE trial in rural Lesotho**
Labhardt, N; Ringera, I; Lejone, T; Muhairwe, J; Fritz, C; Klimkait, T; Glass, T (Basel, Switzerland)*
-
- P335 Characterisation of an inmate population followed in an infectious diseases department in the centre of Portugal**
Casella, M; Ascensão, B; Goes, A; Pinto Luís, N; Messias, A; Brito, A; Joana, S; Poças, J (Setúbal, Portugal)*
-
- P336 Rationales for indicator conditions based HIV testing data from the Emergency Department in the Hospital for infectious diseases in Warsaw**
Pyziak-Kowalska, K; Kowalska, J; Horban, A (Warsaw, Poland)*
-
- P337 The changing epidemiology of newly diagnosed HIV-infected adults in New York City**
Patterson, B; Zucker, J; Ellman, T; Morrison, E; Sobieszczyk, M (New York, USA)*
-
- P338 Reasons for transferring HIV care in London**
Ahmed, N; Scott, D; Waters, L; Matin, N; Whitlock, G (London, UK)*
-
- P339 Atmosphere of risk or family-like support? Alternative patient experiences of decentralized care in North Central Nigeria**
Kolawole, G; Gilbert, H; Dadem, N; Agaba, P; Genberg, B; Agbaji, O; Okonkwo, P; Ware, N (Jos, Nigeria)*
-

Late Presenters

- P340 High mortality attributable to late presentation and delayed ART initiation in HIV-infected adults receiving care in Latin America**
Belaunzarán-Zamudio, P; Shepherd, B; Caro-Vega, Y; Cortés, C; Crabtree-Ramírez, B; Grinsztejn, B; Gotuzzo, E; Mejía, F; Padgett, D; Pape, J; Rebeiro, P; Rouzier, V; Veloso, V; Wagner-Cardoso, S; McGowan, C; Sierra-Madero, J (Mexico City, Mexico)*
-
- P341 Insights into missed opportunities for earlier testing in newly diagnosed patients referred for HIV care to a Swiss teaching hospital between 2010 and 2015**
Lhopitallier, L; Moulin, E; Cavassini, M; Darling, K (Lausanne, Switzerland)*
-
- P342 Is it acceptable to ignore national testing guidelines? Current testing practice in Lothian 8 years after BHIVA national testing guidelines were published**
Cevik, M; Raha, D; Mutch, C; Leen, C (Edinburgh, UK)*
-
- P343 HIV late presenters: a retrospective cohort study on an outpatient clinic in Lisbon, 2010–2014**
Cota-Medeiros, F; Afonso, C; Zagalo, A; Caldeira, L (Lisbon, Portugal)*
-
- P344 Clinical characteristics of newly diagnosed HIV-infected patients and risk factors for late presentation: a Portuguese cohort**
Veiga Ferraz, R; Almeida, F; Duro, R; Pereira, N; Pinero, C; Caldas, C; Serrão, R; Sarmiento, A (Porto, Portugal)*
-

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

Virology and Immunology

- P345 Immune recovery in acute and chronic HIV infection and the impact of thymic stromal lymphopoietin**
Gelpi, M; Hartling, H; Thorsteinsson, K; Gerstoft, J; Ullum, H; Nielsen, S (Copenhagen, Denmark)*
- P346 Neuroasymptomatic cerebrospinal fluid (CSF) viral escape (aCVE) is associated with increased intrathecal immune activation, but not with CSF signs of neuronal injury and alteration of CSF/serum albumin ratio**
Pinnetti, C; Fedele, V; Carta, S; Lorenzini, P; Mazzotta, V; Bordoni, V; Baldini, F; Grisetti, S; Capobianchi, M; Martini, F; Ceccherini-Silberstein, F; Ammassari, A; Perno, C; Antinori, A (Rome, Italy)*
- P347 Cardiovascular risk in HIV-positive subjects: analyses of T-cell phenotype and CD49d expression**
Zingaropoli, M; D'Abramo, A; Iannetta, M; Oliva, A; d'Ettorre, G; Lichtner, M; Mastroianni, C; Ciardi, M; Vullo, V (Rome, Italy)*
- P348 Baseline myeloid and lymphoid activation markers can predict time to viral load reduction under 50 copies/mL and CD4 recovery, respectively, after highly-active antiretroviral therapy initiation**
Iannetta, M; Lichtner, M; Rossi, R; Savinelli, S; Vita, S; Mascia, C; Zuccalà, P; Marocco, R; Zingaropoli, M; Ciardi, M; d'Ettorre, G; Mastroianni, C; Vullo, V (Rome, Italy)*
- P349 Impact of oestrogen plasma levels in modulation of immune activation among HIV-infected women and men undergoing successful antiretroviral therapy**
Marocco, R; Lichtner, M; Tieghi, T; Belvisi, V; Pozzetto, I; Mascia, C; Zuccalà, P; Rossi, R; Mengoni, F; Mastroianni, C (Latina, Italy)*
- P350 Active TGF- β 1 may be involved in viral suppression during ART in HIV-1-infected patients**
Maina, E; Bukusi, E; Sedegah, M; Lartey, M; Ampofo, W (Accra, Ghana)*
- P351 Geno2pheno [coreceptor-hiv2]: a new diagnostic tool for the genotypic determination of HIV-2 coreceptor usage**
Döring, M; Borrego, P; Büch, J; Martins, A; Friedrich, G; Camacho, R; Eberle, J; Kaiser, R; Lengauer, T; Taveira, N; Pfeifer, N (Saarbrücken, Germany)*
- P352 High rates of multi-class drug resistance in HIV-1-infected individuals monitored with CD4 cell count in Uganda**
 *von Braun, A*; Scherrer, A; Sekaggya, C; Kirangwa, J; Ssemwanga, D; Kaleebu, P; Günthard, H; Kambugu, A; Castelnovo, B; Fehr, J (Kampala, Uganda)*
- P353 Prevalence and impact of transmitted drug resistance in recent HIV-1 infections, Germany 2013–2015**
Hauser, A; Hofmann, A; Hanke, K; Bremer, V; Bartmeyer, B; Kücherer, C; Bannert, N (Berlin, Germany)*
- P354 Higher rates for transmission of NNRTI-resistant viruses for subtype A versus subtype B strains in Southern Greece**
Kostaki, E; Sypsa, V; Nikolopoulos, G; Gargalianos, P; Xylomenos, G; Lazanas, M; Chini, M; Skoutelis, A; Papastamopoulos, V; Antoniadou, A; Papadopoulos, A; Psychogiou, M; Daikos, G; Chrysos, G; Papanizos, V; Kourkounti, S; Sambatakou, H; Sipsas, N; Lada, M; Panagopoulos, P; Maltezos, E; Hatzakis, A; Paraskevis, D (Athens, Greece)*
- P355 The absence of drug resistance against dolutegravir in first-line therapy is attributable to reduced viral replicative fitness and durable anti-HIV immune responsiveness**
Wainberg, M; Mesplede, T (Montreal, Canada)*

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P356 Low prevalence of pre-treatment HIV-1 drug resistance in Ugandan adults**
*von Braun, A**; Sekaggya, C; Scherrer, A; Magambo, B; Ssemwanga, D; Kaleebu, P; Günthard, H; Kambugu, A; Fehr, J; Castelnovo, B (Kampala, Uganda)
-
- P357 Prevalence of resistance mutations to rilpivirine and etravirine in people starting antiretrovirals in Argentina**
*Bissio, E**; Barbás, M; Bouzas, M; Cudolá, A; Falistocco, C; Salomón, H (Buenos Aires, Argentina)
-
- P358 Frequency of additional resistance relevant mutations in 2% and 1% population proportions in next-generation sequencing (NGS) in routine HIV-1 resistance diagnostics**
*Ehret, R**; Moritz, A; Schuetze, M; Obermeier, M (Berlin, Germany)
-
- P359 Impact of baseline NNRTI resistance in antiretroviral-naïve patients in a large urban clinic**
*Steinberg, S**; Crouzat, F; Sandler, I; Varriano, B; Smith, G; Kovacs, C; Brunetta, J; Chang, B; Merkley, B; Tilley, D; Fletcher, D; Acsai, M; Knox, D; Sharma, M; Loutfy, M (Toronto, Canada)
-
- P360 Enhanced surveillance to study HIV-1 drug resistance among naïve individuals in Southern Greece: the added value of molecular epidemiology to public health**
*Paraskevis, D**; Kostaki, E; Magiorkinis, E; Gargalianos, P; Xylomenos, G; Lazanas, M; Chini, M; Skoutelis, A; Papastamopoulos, V; Antoniadou, A; Papadopoulos, A; Psychogiou, M; Daikos, G; Zavitsanou, A; Chrysos, G; Papanizos, V; Kourkounti, S; Oikonomopoulou, M; Sambatakou, H; Sipsas, N; Lada, M; Panagopoulos, P; Maltezos, E; Drimis, S; Hatzakis, A (Athens, Greece)
-
- P361 Transmission patterns of HIV-1 subtype A resistant strains across Greece: evidence for country and regional level transmission networks**
*Paraskevis, D**; Skoura, L; Kostaki, E; Gargalianos, P; Xylomenos, G; Lazanas, M; Chini, M; Metallidis, S; Skoutelis, A; Papastamopoulos, V; Antoniadou, A; Papadopoulos, A; Psychogiou, M; Daikos, G; Pilalas, D; Zavitsanou, A; Chrysos, G; Papanizos, V; Kourkounti, S; Chatzidimitriou, D; Sambatakou, H; Sipsas, N; Lada, M; Panagopoulos, P; Maltezos, E; Drimis, S; Hatzakis, A (Athens, Greece)
-
- P362 Occurrence and risk factors for primary integrase resistance-associated mutations in Austria in the years 2008–2013**
*Zoufaly, A**; Kraft, C; Schmidbauer, C; Puchhammer, E (Vienna, Austria)
-
- P363 Transmission of HIV-1 drug resistance in Tel Aviv, Israel, 2010–2015**
*Turner, D**; Girshengorn, S; Braun, A; Tau, L; Leshno, A; Alon, D; Pupko, T; Zeldis, I; Matus, N; Gielman, S; Ahsanov, S; Schweitzer, I; Avidor, B (Tel Aviv, Israel)
-
- P364 Development of T66I-mediated integrase inhibitor cross-resistance against elvitegravir under dolutegravir-containing first-line therapy**
*Wiesmann, F**; Däumer, M; Naeth, G; Knechten, H; Braun, P; Rump, J (Aachen, Germany)
-
- P365 Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing regimens in Taiwan: a multicenter cohort study**
*Cheng, C**; Su, Y; Tsai, M; Yang, C; Liu, W; Cheng, S; Sun, H; Hung, C; Chang, S (Taoyuan, Taiwan)
-
- P366 Association of therapeutic failure with low-level viremia in HIV-infected patients in the Aevir/RESINA cohort in Germany**
*Lübke, N**; Pironti, A; Knops, E; Schülter, E; Jensen, B; Oette, M; Esser, S; Lengauer, T; Kaiser, R (Düsseldorf, Germany)
-
- P367 Drug resistance mutations (DRM) among pregnant HIV-positive women in the Duesseldorf University Hospital, Germany, 2009–2016**
*Haars, U**; Luebke, N; Jensen, B; Haeussinger, D (Essen, Germany)

*Indicates presenting author.

POSTER PRESENTATIONS (continued)

- P368** **Prevalence of HIV type 1 drug resistance mutations in treatment-naïve patients participating in the GARDEL study**
Figuerola, M;* Patterson, P; Cahn, P; Andrade-Villanueva, J; Arribas, J; Gatell, J; Lama, J; Norton, M; Sierra Madero, J; Sued, O; Rolon, M (Buenos Aires, Argentina)
-
- P369** **High prevalence of transmitted antiretroviral drug resistance in newly HIV-1 diagnosed Cuban patients**
Perez Santos, L;* Machado, L; Kouri Cardella, V; Diaz, H; Aragones, C; Aleman, Y; Silva, E; Correa, C; Blanco de Armas, M; Perez, J; Dubed, M; Soto, Y; Ruiz, N; Limia, C; Nibot, C; Valdés, N; Ortega, M; Romay, D; Baños, Y; Rivero, B; Campos, J (Havana, Cuba)
-
- P370** **Viroseq protocol optimized for the detection of HIV-1 drug mutations in patients with low viral load**
Monteiro, F;* Tavares, G; Ferreira, M; Amorim, A; Bastos, P; Rocha, C; Hortelão, D; Vaz, C; Koch, C; Araujo, F; Serrão, R; Sarmiento, A (Porto, Portugal)
-
- P371** **The role of presepsin (sCD14-ST) as an indirect marker of microbial translocation and immune activation**
Paola, C;* Zuccaro, V; Cima, S; Sacchi, P; Bruno, R (Pavia, Italy)
-
- P372** **CRF19_cpx variant emergence in a cluster in naïve patients of southern Spain: clinical and phylogenetic characterization**
González-Domenech, C;* Viciano, I; Mayorga, M; Palacios, R; de la Torre, J; Jarilla, F; Castaño, M; del Arco, A; Márquez, M; Clavijo, E; Santos, J (Málaga, Spain)
-
- P373** **One-step real-time PCR for HIV-2 group A and B RNA plasma viral load in LightCycler 2.0**
Bastos, P; Monteiro, F*; Tavares, G; Amorim, A; Ferreira, M; Hortelão, D; Rocha, C; Vaz, C; Koch, C; Araujo, F; Serrão, R; Sarmiento, A (Porto, Portugal)
-
- P374** **The association between high pre-HAART CD8 cell counts and poorer immunological outcome following antiretroviral therapy**
Wong, C;* Wong, N; Lee, S (Hong Kong, Hong Kong)
-

*Indicates presenting author.